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Abstract 
 
Benzalkonium chloride (BAC), is the most commonly used preservative world-wide in cosmetics and 
eye drops; however, it is toxic to epithelial cells and the pathways in this toxicity are largely unknown. 
In this study, the effects of common ophthalmic drugs for glaucoma were uncovered by exposing 
human corneal and conjunctival epithelial cells (HCE and IOBA-NHC respectively) to treatments 
with and without BAC. It was hypothesized that these drugs may be linked to inflammatory 
mechanisms and cell death. The aim of this study was to explore proteomic data in order to discover 
some potential biomarkers relating to BAC-induced effects, which could be beneficial in further 
studies. 
HCE and IOBA-NHC cells were exposed to a preservative-free topical medication tafluprost, a 
similar drug latanoprost which contains BAC or BAC by itself for 24 hours and then the proteomic 
profiles of treated and untreated cells were analysed with NanoLC-TOF-MS using SWATH 
technique. Central tendency normalization was applied to the log2-transformed proteomic data once 
the quality of the data was initially ensured with descriptive statistics including correlation and 
clustering methods. Mixed-effects ANOVA model was implemented to data to uncover differentially 
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expressed protein levels and Benjamini-Hochberg procedure was used for multiple testing correction. 
All these procedures were performed using R software. 
Statistical analysis identified 29 differentially expressed proteins for IOBA-NHC cells (fold 
change>1.25 or <0.8, q-value<0.25) and 28 for HCE cells (fold change>1.5 or <0.67, q-value<0.25). 
Based on the significance estimations, enrichment analyses were performed using several online 
tools, including GOrilla and DAVID tools. After examining both individual statistically and 
biologically significant proteins and the enrichment analyses results for both cell lines, it appeared 
that changes in mitochondrion functions are affected by exposure to BAC. This was supported by the 
enrichment analyses and in addition NDFUA5 and NDUFS3, proteins associated to the mitochondrial 
membrane respiratory chain NADH dehydrogenase, were under-expressed for BAC-treated samples 
in IOBA-NHC cell line. Furthermore, in both cell lines the cholesterol production and therefore the 
plasma membrane permeability and structure could be altered due to reduced abundance of 
HMGCS1, which is an essential catalyst in this process. In addition, actin cytoskeleton contractions 
were at least in the HCE cell line increased, which then in turn could affect the permeability of the 
cell junctions. This was initially noted due to the over-expression of MYH9, MYL12A and MYL6 in 
HCE cell line samples treated with BAC. These potential novel proteomic biomarkers will be further 
analysed in ongoing clinical studies of glaucoma patients. 
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Tiivistelmä 
 
Bentsalkoniumkloridi (BAC), on maailmanlaajuisesti yleisimmin käytetty säilöntäaine kosmetiikassa 
ja silmätipoissa; se on kuitenkin myrkyllistä epiteelisoluille ja tähän myrkyllisyyteen johtavat 
solunsisäiset reitit ovat suurelta osin edelleen tuntemattomia. Tässä tutkimuksessa yleisten 
glaukoomalääkkeiden vaikutuksia tutkittiin altistamalla ihmisen sarveiskalvon ja sidekalvon 
epiteelisoluja (HCE ja IOBA-NHC) käsittelyihin, joista osa sisälsi BAC-säilöntäainetta. Hypoteesina 
oli, että nämä säilöntäaineita sisältävät lääkkeet voisivat aiheuttaa soluissa muutoksia, jotka liittyvät 
tulehduksellisiin mekanismeihin ja solukuolemaan. Tavoitteena oli identifioida proteomiikka datan 
avulla potentiaalisia biomarkkereita, jotka ilmaisisivat BAC-säilöntäaineen vaikutuksia soluissa. 
HCE ja IOBA-NHC solut altistettiin joko säilöntäaineettomalle tafluprostille, samankaltaiselle BAC-
säilöntäainetta sisältävälle latanoprostille tai pelkästään BAC-säilöntäaineelle 24 tunnin ajan ja 
näytteet analysointiin NanoLC-TOF-MS-laitteella SWATH-tekniikkaa käyttäen. Log2-transformoitu 
data normalisoitiin mediaani-normalisointia käyttäen sen jälkeen, kun näytteiden laatu oli ensin 
vahvistettu alustavien kuvaajien ja metodien, mm. korrelaation ja klusteroinnin, kautta. Tilastollisessa 
analyysissa käytettiin sekamallia ja Benjamini-Hochberg-menetelmää sovellettiin p-arvojen väärien 
positiivisten löydösten kontrolloimiseen. Kaikki yllämainitut menetelmät tehtiin käyttäen R-
tietokoneohjelmaa. 
Tilastollinen analyysi identifioi 29 tilastollisesti mielenkiintoista proteiinia IOBA-NHC solujen 
näytteistä ja 28 vastaavasti HCE solujen näytteistä. Tilastollisten tulosten perusteella tehtiin 
rikastusanalyyseja useilla verkko-ohjelmilla, joihin kuuluivat mm. GOrilla ja DAVID. Kun sekä 
yksittäiset, mielenkiintoiset proteiinit että rikastusanalyysien tulokset käytiin läpi, tulokset viittasivat 
siihen, että BAC vaikuttaa mitokondrioon ja siihen liittyviin mekanismeihin soluissa, 
soluhengitykseen erityisesti. Tätä tukevat sekä rikastusanalyysien tulokset sekä se, että NDFUA5 ja 
NDUFS3, jotka liittyvät mitokondrion prosesseihin, olivat aliekspressoituneita IOBA-NHC 
näytteissä, jotka oli altistettu BAC-säilöntäaineelle. Lisäksi, molemmissa solulinjoissa kolesterolin 
tuotanto ja sitä kautta solukalvon läpäisevyys saattaa muuttua alentuneen HMGCS1:n johdosta. 
Lisäksi ainakin HCE-solujen tuloksissa oli viitteitä nousseeseen aktiinitukirakenteiden supistusten 
määrään, sillä MYH9, MYL12A ja MYL6 olivat yliekspressoituja näytteissä, jotka oli altistettu BAC-
säilöntäaineelle. Tämä voi osaltaan vaikuttaa solujen liitosten läpäisevyyteen. Nämä potentiaaliset 
biomarkkerit tullaan analysoimaan tarkemmin tulevien kliinisten tutkimusten avulla. 
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Abbreviations 
Abbreviation Meaning 
ACG Angle closure glaucoma 
ANOVA Analysis of variance 
ARACNE Algorithm for the Reconstruction of Accurate Cellular Networks 
BAC Benzalkonium chloride 
BP Biological process 
CAI Carbonic anhydrase inhibitors 
CC Cellular component 
DAVID Database for Annotation, Visualization and Integrated Discovery 
DIA Data-independent acquisition 
ES Enrichment score 
FDR False discovery rate 
GO Gene ontology 
GOrilla Gene Ontology enRIchment anaLysis and visuaLization tool 
GSEA Gene set enrichment analysis 
HCE Human corneal epithelial cells 
HK2 Hexokinase-2 
HMGCS1 Hydroxymethylglutaryl-CoA synthase, cytoplasmic 
IOBA-NHC Immortalized normal human conjunctival epithelial cells 
IOP Intraocular pressure 
IPI International protein index 
iTRAQ Isobaric tag for relative and absolute quantitation 
KEGG Kyoto encyclopaedia of genes and genomes 
LC Liquid chromatography 
MF Molecular function 
MI Mutual information 
MLC Myosin light chain 
MRM Multiple reaction monitoring 
MS Mass spectrometry 
MYH9 Myosin-9 
MYL12A Myosin regulatory light chain 12A 
MYL6 Myosin light polypeptide 6 
NDUFA5 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 
NDUFS3 NADH dehydrogenase [ubiquinone] iron sulphur protein 3, mitochondrial 
OAG Open angle glaucoma 
OSD Ocular surface disease 
ROS Reactive oxygen species 
SRM Selected reaction monitoring 
SWATH Sequential window acquisition of all theoretical spectra 
WST-1 Water-soluble tetrazolium salt 
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1 Introduction 
 
Glaucoma is a progressive optic neuropathy characterized by structural and functional changes in 
ganglion cell axons of the optic nerve (Salim, 2012). These changes can eventually result in a loss of 
vision if the condition goes untreated. The underlying causes of glaucoma are still largely unknown, 
but it is known that high intraocular pressure (IOP) is one of the main risk factors of glaucoma (Lang, 
2007). Hence, glaucoma is usually treated by using mainly topical medication, laser therapy or 
surgery, which aim to decrease IOP. Currently approximately 60 million people are affected by 
glaucoma and this figure is expected to rise considerably in the future (Quigley & Broman, 2006).  
Topical treatment of chronic glaucoma can in many cases have consequences that reduce the efficacy 
and safety of the medical therapy. Such consequences include ocular surface changes (Pisella et al., 
2002), cataract development (Chandrasekaran et al., 2006) and topical anti-glaucoma treatments are 
also connected to increased risk of failure in other types of therapies such as surgery (Broadway et 
al., 1994). Furthermore, as also described by Pisella et al. (2002) some patients are known to be more 
sensitive to the drugs and their adjunctive agents such as preservatives, which are present in the 
topical treatments. In addition, the use of preservative containing topical medications has been 
associated to the development and worsening of ocular surface diseases (OSD) (Zhou & Beuerman, 
2012). Especially benzalkonium chloride (BAC), which is the most common preservative used in eye 
drops, has been linked to adverse effects in some patients as it is known to not only protect the 
ophthalmic solution from microbial contamination but also to be cytotoxic to cells of the surface of 
the eye (Badouin et al., 2010). Several studies have demonstrated the apoptotic effects of BAC on 
various cell lines (Epstein et al., 2009; Furrer et al., 2002), yet the pathways leading to this effect are 
not fully known. 
The aim of this study was to examine the proteomic profiles of epithelial cell lines, which were 
exposed to either BAC-containing or preservative-free treatments and to identify individual proteins 
which play a role in the cellular reactions caused by preserved glaucoma medication in the cell lines. 
More specifically, corneal and conjunctival epithelial cells were exposed to preserved latanoprost, 
unpreserved tafluprost and preservative BAC. By identifying some statistically significant protein 
expression level changes between the treatments, it was hoped that some further information could 
be gained from the underlying pathways which cause cell apoptosis and other adverse effects in cells 
which are exposed to preservatives. In addition, enrichment analysis was applied once differentially 
expressed proteins were identified to further broaden the understanding of biological aspects. The 
results obtained from this study could be later on validated in further studies. 
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2 Review of literature 
 
Many patients suffering from an ophthalmic condition are likely to be subjected to various topical 
medications during the time of their treatment, which for example in the case of glaucoma, can last 
for several years or even decades (Freeman & Kahook, 2009). Many topical treatments, most 
importantly multiple-dose eye drops, contain some form of preservatives or a mixture of them. The 
benefits of added preservatives include limiting the microbial proliferation and preventing any 
unwanted alterations in the formula during the time of use (Baudouin et al., 2010). However, 
preservatives are often also cytotoxic for the epithelial cells of the ocular surface and due to this, 
patients who are subjected to long-term medication containing preservatives, may also experience 
unwanted side effects (Pisella et al., 2002). These adverse effects are often allergic or inflammatory 
symptoms varying from redness, stinging, burning, irritation and eye dryness to occasionally 
conjunctivitis or corneal damage (Baudouin et al., 2010). Not only is the duration of exposure a factor, 
but it has further been explained that the unwanted symptoms appear to be proportional to the 
concentration of the preservative, i.e. a larger proportion of a preservative often means a greater 
reaction (Uusitalo et al., 2010). Recent studies have shown that by switching from a preserved 
multiple-dose eye drops to preservative-free formulations, patients who suffered from adverse effects 
during the use of glaucoma medication containing preservatives, have experienced reduction in their 
allergic and inflammatory signs and symptoms after switching to preservative-free medication, whilst 
still maintaining a lowered level of IOP (Uusitalo et al., 2010; Pisella et al., 2002). 
 
2.1 Glaucoma 
 
Glaucoma is a term describing a group of neurodegenerative diseases causing progressive optic 
neuropathy due to loss of retinal ganglion cells and it is the second leading cause of blindness 
worldwide (Quigley & Broman, 2006). In a majority of glaucoma cases, the aqueous humor formed 
by the ciliary body is not successfully drained from the eye through trabecular outflow pathways as 
it should, resulting in unusually high IOP levels in the eye (ocular hypertension) which causes optic 
neuropathy (Wiggs, 2007). Most commonly, glaucoma takes place later in life as the risks to obtain 
glaucoma are significantly increased after the age of 40 and early-onset glaucoma is less common 
(Lang, 2007).  
The two main types of glaucoma, i.e. open angle glaucoma (OAG), which is the most predominant 
one of all glaucoma groups, and angle closure glaucoma (ACG) are affecting over 60 million people 
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worldwide, and it is estimated that the number of affected individuals will increase to 79.6 million by 
2020 (Quigley & Broman, 2006). OAG and ACG are differentiated by the status of the angle between 
iris and the cornea and in OAG this angle is open but the aqueous humor outflow through trabecular 
meshwork has gotten blocked slowly overtime and the normal outflow of humor is this way prevented 
(Lang, 2007). The slow development of this blockage is the reason why many patients only discover 
noticeable symptoms later on in the process of the condition when it has already developed further 
and some level of vision loss has already occurred (Kroese & Burton, 2003). Figure 2.1.1 visualizes 
the effects of the blockage in the eye. 
 
Figure 2.1.1 Comparisons of normal eye and eye with glaucoma (modified from a picture by Thomas Bond & Partners, 
2013). In the eye with glaucoma, the trabecular meshwork has been blocked preventing the aqueous humor flow, which 
results in pressure in the eye and hence damage to the optic nerve. 
 
In ACG the blockage is more sudden and it is caused by a quick increase in the IOP which is causing 
the iris to occlude the trabecular meshwork causing blurred vision, severe eye and head ache, nausea 
and sudden sight loss are often quickly noticed by the patient (Lang, 2007). This type of glaucoma 
requires immediate treatment. The discussion of glaucoma in this study will refer usually to primary 
OAG, which instead of ACG requires long-term topical treatment of the condition, even though some 
aspects may be applicable to other types of glaucoma as well.  
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The word “primary” or “secondary” added in the front of the glaucoma type refers to the cause of 
glaucoma. Primary refers to glaucoma that is not caused by any other ocular disorders and secondary 
indicates that the glaucoma may be a result of another ocular disorder or a side effect from another 
treatment (Lang, 2007; Kroese & Burton, 2003). 
One of the main and most well-known risk factors of glaucoma is elevated IOP, though it is no longer 
considered the only distinctive factor as it has been discovered that the presence or absence of 
intraocular hypertension does not have a direct causal relationship with glaucoma and it is also 
possible to develop glaucoma where the IOP is considered normal (Noecker, 2006; Lang, 2007). In 
fact it is thought that 25%-50% of POAG patients have what is considered a normal IOP (Kroese & 
Burton, 2003). Normal IOP in adults is approximately 15 mmHg and the threshold for intraocular 
hypertension is considered to be at 21 mmHg. 
Other risk factors connected to glaucoma include old age, African origin, myopia and family history 
of glaucoma (Kroese & Burton, 2003). Additionally certain medical conditions, e.g. diabetes, high 
blood pressure are considered risk factors and furthermore, vascular dysregulation is considered to 
be linked to glaucoma (Lang, 2007). Despite the knowledge of risk factors, the underlying causes of 
glaucoma are still largely unknown and therefore instead of trying to identify the general risk factors, 
the research now concentrates on finding particular genes and proteins, which could be responsible 
for causing the condition. The identification of these genes and proteins could then help to develop 
methods of treatment and even prevention of glaucoma. 
Recent studies have identified some of the genes which are thought to be associated with glaucoma 
and early-onset glaucoma can be inherited as a mendelian autosomal-dominant or autosomal-
recessive trait through these genes (Wiggs, 2007). However, the adult-onset glaucoma does not often 
exhibit mendelian inheritance patterns but instead, the condition is a result of interactions between 
multiple genetic factors and the environment also plays a role in the development of the disease 
(Wiggs, 2007). Some further distinctions can be made between the genes associated to POAG. For 
example, mutations in myocilin (MYOC), WD-repeat domain 36 (WDR36) and optineurin (OPTN), 
can cause POAG alone without any further influence from other genes or risk factors (Fingert, 2011). 
Other genes associated with POAG can instead be considered risk alleles, which in the case of 
mutations can promote the development of POAG but these genes are not solely responsible for its 
development. 
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2.2 Treatments of glaucoma 
 
To this date glaucoma is not curable, but through early detection and correct treatment, most often 
topical medication, the development of glaucoma progression towards blindness can be halted or 
delayed (Noecker, 2006). The main aim of topical glaucoma medication is to lower the IOP and stop 
any further glaucomatous damage from occurring in the optic nerve. 
There are different ways the reduction in IOP can be achieved and the main functions are listed in an 
article by Noecker (2006). First approach is that the production of aqueous humor fluid is inhibited 
and the ocular hypotensive agents achieving this include beta-blockers and carbonic anhydrase 
inhibitors (CAIs). Alternatively, with prostamides, prostaglandin analogs or parasympathomimetic 
drugs the trabecular or uveoscleral outflow can be increased. The trabecular outflow is the 
conventional method for the eye to remove the excess aqueous humor into the canal of Schlemm, 
whilst uveoscleral outflow, which is not as effective (Lang, 2007), happens through the ciliary body. 
Furthermore, some agents like α-adrenergic agonists work by combining both of the aforementioned 
methods of reducing IOP, i.e. reduction of aqueous humor production and increase in outflow. It is 
worth noting that occasionally it may be beneficial for the patient to tackle the increased IOP by 
combining multiple medications with different effects (Noecker, 2006). 
 
2.3 Preservatives 
 
Preservatives can cause inflammatory and allergic reactions with some patients. These effects are 
often caused by damage to the cells first in contact with the eye drops, i.e. corneal and conjunctival 
epithelium cells, due to the cytotoxic nature of the preservatives. Despite some unwanted side effects, 
the preservatives provide essential protection for the formulation from any microbial contamination, 
which may occur via the patient’s hands or by other surface areas of the patient whilst applying the 
medication. Further on, the preservatives may help the drug to maintain its potency and prevent any 
possible biodegradation. However, this type of protection is considered to be the task of stabilizing 
agents and not preservatives. (Furrer et al., 2002)  
Preservatives can be divided into two main groups: detergents and oxidizing preservatives (Noecker, 
2001), however many studies increase the number of ophthalmic preservative classes up to four 
(Epstein et al., 2009): detergents, oxidants, chelating agents, and metabolic inhibitors. There are 
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additional division methods based on the preservatives’ chemical classes (Furrer et al., 2002). Only 
the first two major groups, detergents and oxidants, are explained in some further detail.  
The detergents work by altering the lipid component of cell membranes of the affected (microbial) 
cells causing membrane instability (Noecker, 2001). This is different from oxidizing preservatives, 
which instead enter the cell and alter the lipids, proteins and DNA elements inside (Noecker, 2001). 
Both of these methods promote lysis of plasma membrane, inhibition of cellular metabolism, 
oxidization or coagulation of cellular constituents or promotion of hydrolysis (Noecker, 2001). The 
method of action with oxidizing preservatives is considered less drastic compared to detergents, 
however, with sufficiently large doses, both types of preservatives are capable of causing cytotoxic 
effects in eukaryotic cells, leading to inflammation. Since the evidence of harmful effects of 
preservatives, and especially detergent preservatives, has piled up, many new approaches have been 
developed that attempt to tackle the issues with cytotoxic effects, e.g. preservative-free and sustained-
release medications (Kaur et al., 2009). Another new approach is the sofZia (Alcon) preservative 
system, which contains chemical substances, which are not cytotoxic to ocular surface cells but still 
maintain antimicrobial environment in the solution (Kaur et al., 2009). 
 
2.3.1 Benzalkonium chloride 
 
Benzalkonium chloride (BAK or BAC) is one of the most commonly used preservative in topical 
ophthalmic medications. It is classified as a quaternary ammonium compound composed of a mixture 
of alkylbenzyl-dimethylammonium chloride homologues (Epstein et al., 2009). Based on the division 
discussed in the earlier section, BAC could be classified as a detergent-like substance and it is 
considered highly effective due to its ability to efficiently prevent microbial contamination by protein 
denaturation and lysis of cytoplasmic membranes (Noecker, 2001), whilst also affecting the cell 
membrane permeability by allowing the ingredients in the medication to enter the anterior chamber 
by breaking cell-cell junctions in the epithelium (Kaur et al., 2009).  
However, BAC is also known to be interrupting the metabolic processes of the cell, causing lysis of 
the cell contents and allowing vital substances to escape the cell (Epstein et al., 2009). Further on, 
there is evidence showing that BAC induces necrosis and apoptosis in bacterial cells, in 
concentrations of 0.05-0.1% and 0.01% respectively, by disturbing their plasma membrane, as 
desired. Unfortunately these effects can be very similar in human ocular surface cells (Kaur et al., 
2009; Baudouin et al., 2010). BAC also has a tendency to interrupt cell mitosis (Guo et al., 2007) and 
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reduce the tear film breakup time which reduces the tear film stability. This instability can heighten 
the risk for adverse effects in particular with patients suffering from dry eye syndrome, and this is 
particularly prevalent with patients also suffering from glaucoma as they have a decreased rate of 
basal tear turnover (Kaur et al., 2009). Therefore, patients suffering from both of the conditions 
mentioned above, i.e. dry eye and glaucoma, are highly susceptible to encounter the adverse effects 
of BAC. 
In a study by Epstein et al. (2009) cytokines in BAC-treated cells were quantified via enzyme linked 
immunosorbant assays cells and it was shown that cells treated with BAC contain significantly 
increased quantities of two well-known inflammation biomarkers; interleukin (IL-) 1 and tumor 
necrosis factor (TNF𝛼). In addition, some other inflammation-related markers increased moderately. 
Further on, some ex vivo observation studies on rabbits have shown that even after a short period of 
exposure, some corneal and conjunctival damage starts occurring and these effects are more severe 
when higher concentrations of BAC are applied (Furrer et al., 2002). The epithelial cells in the eye 
can be damaged by the cytotoxicity of BAC and this effect can be notable since the epithelial cells 
form the protective barrier in the surface of the eye (Guo et al., 2007). 
 
2.4 Epithelial conjunctival and corneal cell lines 
 
2.4.1 Conjunctival epithelial cell line (IOBA-NHC) 
 
The conjunctiva is a smooth, continuous membrane which lines not only the inside of the eyelid 
(palpebral conjunctiva) but it also covers the sclera around the cornea (bulbar conjunctiva). This can 
be seen illustrated in Figure 2.4.1.1. The conjunctival epithelium helps to maintain healthy ocular 
surface and physiological changes in it are thought to be connected to inflammatory diseases of the 
ocular surface (Brasnu et al., 2008a). The process of collecting human biopsies is one of the methods 
of obtaining conjunctival epithelium samples. However, these samples are often not ideal for research 
purposes (Brasnu et al., 2008b) and instead, immortalized cell lines are often very popular in research 
studies due to their ease of access and quick cell growth. The reproducibility is also considered better 
than with primary cultures (Brasnu et al., 2008b), which could be considered another alternative to 
cell lines.  
The IOBA-NHC cell line was characterized by Diebold et al. (2003). This spontaneously 
immortalized cell line is commonly used in studies examining and comparing toxicity profiles of 
varying topical medications (Diebold, 2003; Brasnu et al., 2008b). In studies examining the effects 
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of BAC in epithelial conjunctival cell it was noted that cells showed signs of caspase-dependent and 
-independent apoptosis, oxidative stress, increase of cell membrane permeability and cell shrinkage 
and blebbing amongst other typical “symptoms” (Clouzeau et al., 2012; Buron et al., 2006). 
According to a study by Pellinen et al. (2012), IOBA-NHC cells appear to be more sensitive to the 
effects of BAC in comparison to HCE cells. 
 
Figure 2.4.1.1 The structure of the eye from the side (A) and front (B). The conjunctiva layers the sclera around the 
cornea and the inside of the eyelid. Cornea covers the iris and lens. (Modified from a picture by Azari & Barney, 2013) 
 
2.4.2 Corneal epithelial cell line (HCE) 
 
The cornea, is an area covering the iris and bordering the sclera. The cornea is built up from several 
parts and the most anterior layer is the corneal epithelium (see Figure 4.2.1.1). The purpose of the 
corneal epithelial cells is the protection of cornea and hence this is another interesting cell line to 
study in relation to the cytotoxic effects of BAC. As discussed in a study by Guo et al. (2007), BAC 
has a tendency to accumulate in the corneal epithelium as it does not penetrate well through it and 
hence BAC has various effects on this barrier. These effects include the disruption of the barrier 
function, reduced wound healing and interruption of mitosis along with the usual BAC induced effects 
already described earlier. The same study evaluated the effects of BAC in relation to myosin light 
chain, which controls the barrier integrity, adhesion and migration. 
A B 
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The epithelial corneal cell line HCE was established and immortalized by Araki-Sasaki et al. (1995) 
by infecting primary cultured human corneal epithelial cells with a recombinant sv-40-adenovirus 
vector (Huhtala et al., 2002). HCE cell line retains the properties (e.g. well-developed desmosomes 
and abundance of microvilli) of normal corneal epithelial cells. Furthermore, a study comparing the 
cytotoxic effects between HCE and rabbit primary corneal epithelial cell line reached similar 
conclusions and it stated that the HCE “is a better model for studies of the corneal toxicity of drugs” 
(Huhtala et al., 2002). 
 
2.5 Mass spectrometry and proteomics 
 
Genomics has developed into cheaper and faster research topic than it was just a decade ago and it 
continues to develop at a rapid pace and due to this, it is a popular research area. However, where 
genomics can be used to investigate the DNA structure and expression, and this way explain 
phenotypes that present themselves, proteomics does this using proteins and the peptides forming 
them. It could be argued, that in medicine development and in personalized medicine in particular, 
the proteins play an even larger part than the genomic information available since the proteins are 
essentially the end product of the genes and these are the elements in biological systems that the drugs 
are essentially used to target. Many things may occur between the gene and finished gene product, a 
protein, and only the end product is what actually causes effects to take or not to take place. Hence, 
though genomics is naturally still an important aspect of “omics” research, proteomics could also be 
expected to become growingly interesting and popular starting point for research, especially in 
medical research. (Schmidt et al., 2014; Noble & MacCoss, 2012; Kumar & Mann, 2009) 
In proteomics, proteins in given samples can be identified and quantified and there are many methods 
that can be applied to the samples depending on the information requirements and interests. For 
example, it could be of interest to just identify which proteins are present in a given sample, or it 
could be more useful to also obtain the expression levels of the proteins identified in a sample. As the 
quantification processes have evolved quickly in the past years, these days more and more often the 
output from proteomic experiments is more than just a list of proteins. (Kumar & Mann, 2009)  
The main core of the experiments often include liquid chromatography (LC) coupled with mass 
spectrometry (MS). The general workflow of a shotgun MS experiment, can be considered to consist 
of three major parts as explained by Noble & MacCoss (2012). In the first part, the proteins are 
isolated from a mixture, i.e. sample, and they are digested into peptides using a protease. Next, in 
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order to reduce the complexity, liquid chromatography is applied, which separates the peptides based 
on their chemical properties. Finally, third step includes tandem mass spectrometry and the “tandem” 
here refers to the two rounds of mass spectrometry which are applied at this step. At this stage mass 
spectrometer first selects several peptides for fragmentation from the liquid chromatography based 
on an initial analysis of distinction, and this is more specifically referred to as LC-MS. These chosen 
peptides are then processed individually so that fragmentation spectra, referred to as daughter ions, 
of the subpeptides are gathered. These spectra are characterized by mass-to-charge ratio (m/z), 
retention times and intensity (Noble & MacCoss, 2012) and each individual spectrum helps then to 
identify the original peptides, or parent ions, which were fragmented.  
The peptide identification can be achieved with a variety of methods: database search, de novo 
spectrum identification, tag-based methods or library search and of these, the database search is the 
most commonly used (Noble & MacCoss, 2012). Next, and in some cases finally, the protein 
identification takes place. Again, there are programs and different methods available for the execution 
of this part and it should be noted that one main complication in this stage is that some peptides are 
so-called degenerate peptides, which means that they may be present in several proteins and naturally 
this can complicate process down the line if not accounted for (Noble & MacCoss, 2012). 
In order to produce different types of proteomics data, several different methods have been developed 
to meet the needs. For example initially, when no prior information is available of a given sample or 
proteomic profile, shotgun proteomics can provide a good starting point as this takes a “discovery”-
approach to proteomics and the output consists of high-throughput data. In this process, a very large 
number of proteins is essentially identified from complex mixtures and the deepest possible coverage 
of the proteome can be achieved. (Schmidt et al., 2014)  
Another one of the main techniques in proteomics is the targeted MS which is essentially the other 
traditional approach next to shotgun proteomics. In some cases the researcher may already have a 
fairly good idea of the proteins which are of interest in a particular study. Targeted MS methods 
include selected and multiple reaction monitoring (SRM and MRM respectively). Having prior 
information of the proteins of interest can be taken advantage and by focusing on these proteins and 
peptides alone, the sensitivity and reproducibility of the method can be increased significantly. It 
should be noted that targeted and shotgun proteomics can naturally be both performed in the same 
study in order to obtain maximal amount of information of given samples. (Schmidt et al., 2014) 
In shotgun proteomics proteins obtained from a sample of interest are first fragmented into smaller 
and smaller subparts and the final goal is then to solve what these subparts were in the beginning of 
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the process. The reason for this process is that currently, at least with most MS machinery, complete 
proteins are simply too large to be processed as they are without very expensive tools and hence the 
fragmenting and defragmenting is necessary (Noble & MacCoss, 2012). The whole process of MS 
techniques is further visualized in Figure 2.5.1. 
 
Figure 2.5.1 Shotgun and targeted proteomics workflow (modified from a picture by Perez-Riverol, 2014). The track on 
the left illustrates the targeted workflow where the proteins of interest are first identified and, after SRM assay or similar 
has been developed, the concentration of these proteins can be determined. On the right, the discovery workflow shows 
how all proteins are extracted and digested and a spectra is obtained after MS/MS. Once peptides have been identified, 
e.g. via library search, the proteins can be quantified. 
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One of the drawbacks of shotgun proteomics is sensitivity and reproducibility, or the lack of it 
(Schmidt et al., 2014) and this can be overcome by implementing e.g. MRM or other targeted method 
instead. Additionally, the method described above, i.e. shotgun proteomics only identifies the 
existence of proteins although this alone can already provide some indication of the abundance levels 
(Kumar & Mann, 2009). Techniques have been developed which allow quantification in shotgun as 
well as targeted proteomics. These techniques are a collection of approaches including stable isotope 
labelling, spectral counting and peptide chromatographic peak intensity methods. As an example, in 
stable isotope labelling, e.g. isobaric tag for relative and absolute quantitation (iTRAQ) labelling, a 
heavy isotope label is added into some of the samples and this enables absolute rather than relative 
quantification. Semi-quantitative approaches are not widely used as label-free quantification methods 
are becoming more and more popular nowadays (Kumar & Mann, 2009). Label-free methods are not 
considered as precise as isotope labelling, which however is still complicated, expensive and limit 
the sample number (Huang et al., 2015). 
Recently, new MS methods have been produced and the one method of interest in particular is 
SWATH acquisition, which is a data-independent acquisition (DIA) strategy using MS/MS data 
(Perez-Riverol, 2014). SWATH essentially combines the high throughput aspect of shotgun 
proteomics and the SRM’s ability to produce accurate, complete and reproducible data (Collins et al., 
2013). In SWATH, the peptides are continuously fragmented in fixed windows and the results are 
matched to a spectral library, which has been previously produced using shotgun proteomics (Huang 
et al., 2015). The resulting output, as already mentioned, is a high throughput data with high accuracy 
and it depends on the prior information (library) obtained in an earlier stage.  
 
2.6 Statistical methods with quantified proteomics data 
 
Once quantified proteomics data have been produced, the next step is the statistical analysis. 
Following subsections will discuss different statistical methods, which can be implemented to this 
type of data. 
 
2.6.1 Reduction of bias 
 
All measurement data are subject to degree of bias and noise. This can be caused by several systematic 
and random measurement errors and hence, before proceeding to any differential expression analysis, 
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these aspects should be evaluated and, if necessary, adjusted. In addition to bias, data can have 
extreme measurements present, which can skew the results if not accounted for correctly. (Callister 
et al., 2006; Karpievitch, Dabney, & Smith, 2012) 
One way to reduce and smoothen the effects of extreme measurements is data transformations. For 
example log2-transformation, where each observation is converted to log2-scale, has several 
advantages. As explained in an article by Callister et al. (2006), “it converts the distribution of ratios 
of abundance values of peptides into a more symmetric, almost normal distribution”. Furthermore, 
the article goes on to describe that this type of transformation also allows the use of many robust 
normalization techniques developed for this type of data, as it reduces the leverage of a low number 
of highly abundant species on the regression analysis used by these robust techniques. For these 
reasons, this technique is also very commonly used with microarray data. 
Central tendency normalization, also known as global adjustment, is a method that is implemented in 
order to reduce systematic bias between biological replicates and it is quite common in proteomics 
data analysis. This method essentially subtracts a chosen measure, e.g. mean or median, from each 
observed value (1), which in other words means that “distribution of the log intensity values to center 
around a constant such as mean, median or some fixed value for each sample” (Karpievitch, Dabney, 
& Smith, 2012). In this particular analysis, median of each biological replicate is subtracted from 
each (log2-transformed) individual observation of that biological replicate. This then results in the 
assumption that a large amount of the protein abundances remain unchanged. The formula below 
shows the process: 
                                                                    𝑥𝑖,𝑗
′ = 𝑥𝑖,𝑗 − 𝜇𝑗 ,                                                              (1) 
where 𝑥𝑖,𝑗 is the ith protein abundance value in the jth sample, 𝜇𝑗 is the median of the jth sample and 
𝑥𝑖,𝑗
′  is the resulting normalized value. This method further has benefits when it comes to the 
differential expression analysis as the observed protein abundances are now centered around zero as 
a result. 
Ideally, this method further enables the differentially expressed proteins to become more identifiable, 
whilst differences between random fluctuations are “smoothened”. However, it should be noted that 
unfortunately all normalization will at the same time also result in loss of some information (Hu & 
He, 2007). The aim is to minimize the bias, whilst also making sure that the loss of actual information 
is kept as small as possible. It should be in addition noted, that this sort of normalization does not 
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eliminate systematic trends which sometimes occur in the data (Karpievitch et al., 2012) and therefore 
MA-plots can provide importantly further information of any possible underlying biases. 
 
2.6.2 Technical replicates 
 
Technical replicates are more specifically replicates, which have been obtained from the same 
biological replicate, i.e. sample, and hence they cannot be though to be separate observations and are 
not considered fully independent of each other. Ideally, a data should consist of several biological 
replicates, which could be considered independent, as the scope of conclusions can become very 
limited when approaching data with only technical replicates as mentioned in the review article by 
Cui and Churchill (2003). This aspect should be accounted for in the pre-processing and in choice of 
statistical methods in particular. 
It should be noted that there are different approaches that can be taken with technical replicates. More 
specifically, it is possible to keep the technical replicates separate or alternatively take a chosen 
statistic, often arithmetic or geometric mean of the technical replicates, given that there are no large 
differences between them. The variability between technical replicates can be evaluated for example 
by using MA-plots or correlation measures. Whatever the decision is with the pre-processing of 
technical replicates, it should be noted that these cannot be treated as independent observations of 
each other similar to biological replicates. Hence, as done in this work, when the technical replicates 
are kept separate, the statistical methods used should be capable of taking the non-independence into 
account as well by applying more complex methods, such as mixed-model analysis of variance 
(ANOVA). (Cui & Churchill, 2003) 
 
2.6.3 Differential expression 
 
After establishing the initial quality of the data and performing the necessary transformations and 
normalizations, the next step is to establish, if any statistically and biologically significant differences 
occur between the cellular states (Kumar & Mann, 2009). Several statistical tools can be implemented 
here depending on the structure of the data and research question of the study. 
Mixed-effects model is a statistical model, which could be considered a more evolved version of the 
repeated measures ANOVA in the sense that in addition to the ability to take into account repeated 
or connected measures, it can also account for various other aspects such as a nested structure. As 
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described by Cui and Churchill (2003) mixed models are one option in the case where data is 
constructed hierarchically or there are non-independent replicates involved. Mixed models treat some 
of the factors in an experimental design as random samples from a population and these factors are 
modelled as sources of variance.  
 
2.6.4 Multiple testing correction 
 
One issue, which should be taken into account before identifying the differentially expressed proteins, 
is the multiple testing issue. For example, when around 2,000 proteins are quantified, the testing for 
differential expression will be also done approximately 2,000 times since each protein is tested 
individually. This means that we could expect to observe approximately 100 p-values below 0.05 just 
by chance. These would be considered false positives if no true underlying difference was indeed 
present and the p-value had occurred just by chance. Hence, as the number of tests increases, so does 
the number of false positives. These issues, more specifically multiple comparison issues, should be 
controlled carefully. (Gutstein et al., 2008) 
One option to account for the multiple testing is to adjust the obtained p-values using one of the 
common multiple testing corrections, e.g. Bonferroni correction and Benjamini-Hochberg correction. 
The two methods mentioned above are perhaps the most commonly used correction methods and the 
Bonferroni correction is often considered far too conservative for this type of data, resulting in an 
increased number of false negatives (Gutstein et al., 2008). Benjamini-Hochberg, which allows to 
control the FDR, will produce corrected p-values, also known as q-values, which will tell the 
proportion of false positives observed in the data when a given threshold is chosen. For example, with 
a q-value threshold of 0.1, 10% or fewer are expected to be false positives (Gutstein et al. 2008). The 
classical threshold for statistical significance is often 0.01 or 0.05. 
 
2.6.5 Thresholds 
 
Once the coefficient estimates or other measures relating to biological differences and corresponding 
p-values, with necessary adjustments, are obtained for all of the quantified proteins, it is time to 
evaluate, which one of them could be considered interesting, i.e. statistically significant. 
Two aspects should be taken into account: fold change and the adjusted p-value. The first, fold 
change, tells about the effect size of the difference, i.e. how far apart two mean values are from each 
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other. However, when the variability between individual points in a group is large, this may skew the 
fold change estimates and produce extremely large fold changes even when no true statistically 
significant difference exists between groups. Hence, the p-values, or q-values, provide further 
valuable information at the same time. Yet, just relying on p-values alone is not desirable as the 
differences detected this way could be so small that no biological significance could be derived from 
the results (McCarthy & Smyth, 2009). Traditionally, fold changes above 1.5 or 2 are considered 
interesting. A fold change of 2 means that the quantity changes two-fold, i.e. in layman’s terms it 
doubles. 
 
2.6.6 Network reconstruction 
 
Network reconstruction can be used to establish theoretical connections between the proteins of 
interest. Algorithm for the Reconstruction of Accurate Cellular Networks (ARACNE) is one such 
algorithm, which can be used for the process of network reconstruction (Margolin et al. 2006).  
ARACNE uses expression profiles and the original article by Margolin et al. (2006) used microarray 
expression profiles to demonstrate its functions. As explained in the article, it works by first 
establishing mutual information (MI) measures for pairs of proteins. Mutual information measure 
tells how much information one variable, here a protein, contains about another variable, i.e. another 
protein (Cover & Thomas, 1991). The MIs are then filtered based on a chosen threshold computed 
for a specific p-value (Margolin et al. 2006). Next, the algorithm removes indirect candidate 
interactions and this step bases heavily on the data processing inequality (DPI). This step enables that 
the number of false positive interactions is reduced, which could otherwise arise due to the co-
regulation of genes, or proteins in this case. The resulting networks can then be visualized using for 
example Cytoscape or other similar tool. 
 
2.6.7 Enrichment analysis and tools 
 
Once the differentially expressed proteins are identified using a chosen method and thresholds, the 
next question is: what do these interesting proteins have in common and are they related to any 
specific pathway etc. in the cell, which could explain the changes we are for example clinically 
observing? Enrichment analyses essentially provide information about any chosen enriched GO terms 
or pathways. More specifically, the algorithm identifies, by performing hypergeometric-based tests, 
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terms which are containing so many of the interesting proteins, that it can be considered statistically 
unlikely that this could occur by chance (Falcon & Gentleman, 2007). Hence, it could then be 
expected that the changes observed in the cellular systems and such are somehow connected to a 
given enriched GO term or for example KEGG term (Kyoto Encyclopedia of Genes and Genomes, a 
biological pathway database) term.  
There are few notable further aspects in the GO terms. First, they are ordered hierarchically and hence 
there can be highly similar terms showing up as enriched. In these cases it is up to the user to define, 
which is the most descriptive term which could be used and in addition the number of genes and 
enrichment score (ES) should be kept in mind. Secondly, the GO annotations are divided into three 
main groups: biological process (BP), cellular component (CC) and molecular function (MF) (Huang 
et al., 2009 (1)). All of these will be checked in the analyses further on. 
There are different approaches to performing enrichment analysis. One alternative is that a list of 
interesting proteins, often referred to as candidate proteins, and a background set, also known as 
“protein universe”, are required. This approach is more commonly referred to as singular enrichment 
analysis (SEA) (Huang et al., 2009 (1)). Here the list of interesting annotations therefore includes 
annotations obtained from a differential analysis, which have satisfied chosen thresholds. Further on, 
the background, is usually the list of all proteins in a given data, i.e. both the candidate proteins and 
the proteins which are not considered differentially expressed. However, the background could also 
be considered to be the total species-specific genome or proteome. In any case it should be noted that 
the choice of the background also has an effect on the results (Falcon & Gentleman, 2007). 
Another approach to enrichment analysis is that the user first orders the full list of quantified proteins 
based on some obtained measure, this method is referred to when discussing gene set enrichment 
analysis (GSEA) (Subramanian et al., 2005; Mootha et al., 2003). This measure could for example be 
a correlation coefficient or indeed log2 fold change as is available in this analysis. Here it should be 
noted that the limits between interesting and not interesting proteins are not as clear as in the earlier 
approach and results are likely to be different. Whichever approach is chosen, the multiple 
comparison issue is encountered again and this is why most tools provide several p-value measures 
for the enriched terms and it is up to the user’s discretion which adjustment and threshold is used 
(Huang et al., 2009 (1)). 
26 
3 Aims of the study 
 
This study had more than one aim. Firstly, it was performed in 
order to merely test if, and how well, this type of study could 
be performed successfully. More specifically, it was of interest 
to examine how immortalized cell lines would respond to 
these treatments with these specific concentrations and how 
the resulting proteomics would turn out. This type of study has 
not previously been performed using MS SWATH method.  
The aim of this study was not to tell that all preservatives are 
bad and should not be used in any topical treatments of 
glaucoma. Instead, it should merely be acknowledged that 
there is a subgroup of patients who are currently not 
benefitting from the medication provided for them and other 
alternatives could be more favorable for them. In addition, it 
could be expected that in the future, new and hopefully less 
harmful preservatives are developed to replace the current 
ones at least partially, whilst also the popularity of 
preservative-free treatments could also be expected to rise. By 
examining the pathways and effects of BAC, perhaps some 
new approaches to the topical medications and their 
ingredients could be revealed. 
The second aim of this study, which is what this paper is 
mostly concentrating on is, what proteins are showing 
different abundance levels between the treatments and what 
could explain these differences in a larger, biological scale. It 
was hoped, that once these proteins, and their place in the vast 
network of biological processes was established, a few chosen 
ones could be further verified in following studies. Once a 
confirmation of the effects of BAC in a proteomic level can be 
achieved, it can assist in the development of new medication 
or in fact new preservatives, which could be beneficial 
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Figure 3.1 Flowchart of the steps 
taken in this study. The tasks in the 
grey boxes were done prior to the 
start of this thesis and the blue 
boxes show the tasks described in 
more detail in this study. Some 
tasks are excluded from the start. 
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particularly to those patients needing long-term ophthalmic topical treatment who are sensitive to this 
very common preservative. 
The steps taken to achieve the goals of this study are visualized in Figure 3.1, where it can be seen in 
more detail, which steps/tasks were carried out prior (grey boxes) and during (blue boxes) this study. 
By completing these tasks, it was hoped that the results could then be used to assess and answer the 
research questions outlined here. 
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4 Materials and methods 
 
This section describes the steps taken in the research from sample preparation and processing to the 
actual analysis of the obtained data. For clarity, there are two main subsections; the first one 
concentrates on the sample treatments, their preparation and the mass spectrometry processing carried 
out with the samples and the second subsection discusses the various statistical analysis tools used in 
further processing of the obtained data. 
 
4.1 Study material 
 
As discussed previously, HCE and IOBA-NHC were used in this study to examine the cytotoxic 
effects of BAC. One reason for collecting this type of data was to see if producing reasonable data 
from cell lines was in fact possible as studies exactly like this have not been performed previously. 
Other alternatives to this type of data collection exist, e.g. tear samples from patients, but the interest 
here is cell lines in particular. 
Sample preparation consisted of exposing the HCE and IOBA-NHC cells to either preservative-free 
prostaglandin tafluprost (Talfotan® 15 µg/ml, Santen), preserved latanoprost (Xalatan® 50 µg/ml, 
Pfizer) or preservative BAC for 24 hours. Xalatan contains high concentrations of BAC (0.02%) 
unlike Talfotan, which is a preservative free medication but both a contain prostaglandin as the 
effective agent. In addition, samples with no additional treatment were included as controls. Hence, 
a total of four different sample groups, with varying number of biological replicates for HCE and 
IOBA-NHC cell lines, were processed and analysed for both cell lines. 
The water-soluble tetrazolium salt (WST-1) assay (Roche) was used to evaluate the cytotoxicity of 
treatments and it is based on functions of mitochondrial dehydrogenase enzymes as an indication of 
cellular growth and viability; hence, it enables the approximation of cytotoxicity via loss of cells.  
Figure 4.1.1 indicates the results of the WST-1 cytotoxicity test after treating the cells with different 
glaucoma drugs. When the dilution rate is increased from 1:300 towards 1:20, the cell survival for 
BAC- and latanoprost-treated cells drops dramatically to only few percent. However, tafluprost-
treated cells have a very good survival rate throughout, on average over 90% in all dilutions for both 
cell lines. For the purposes of this study, a dilution of 1:300, with 24 hour exposure, was chosen for 
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latanoprost and tafluprost and an 
equivalent dilution of 0.000067% 
was used for BAC. This way it can 
be assumed that whilst the cell 
survival is still relatively high, the 
effects of BAC could be observed in 
the proteomic profiles of these 
samples. Hence, all following 
processing methods and analysis 
relate to these parameters. 
For each cell line, three biological 
replicates were then produced of 
treated and untreated cells and their 
proteomic profiles were analysed 
with NanoLC-TOF-MS using 
SWATHTM. The structure for each 
individual cell line can be seen in 
Table 4.1.2. One of the sample 
groups for the HCE cell line was 
damaged during sample processing 
and could not be included in the 
analysis and therefore HCE data only 
has two biological replicates for each 
treatment. Otherwise the structure of 
the data remains the same as shown in 
the table below. The SWATH library 
for >2700 proteins was created from the samples and 2299 and 1920 proteins using ProteinPilot and 
PeakView and Marker Viewer were used to match and relatively quantify the results respectively for 
IOBA-NHC and HCE cells. False discovery rate (FDR) of 1% was applied to the analysis. 
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Figure 4.1.1 The cytotoxicity of different treatments was 
evaluated with water-soluble tetrazolium salt (WST-1) assay 
(Roche) in order to identify an ideal exposure concentration to be 
used further on in the study. The results obtained with untreated 
control cells were set as 100% and the BAC concentration in BAC-
treated sample is kept equal to the corresponding exposure of BAC 
in preserved latanoprost. As the figures indicate, the cell survival 
is over 80% for all treatment groups in both A) IOBA-NHC and 
B) HCE cell lines when the dilution is 1:300 for tafluprost and 
latanoprost. 
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One additional important aspect of the data, which should be noted here is that in a sense the data is 
organized in an ordinal manner. More specifically, the data for each cell line is structured so that the 
proteins in the top rows of the matrix, have a better quantification quality when compared against the 
proteins in the bottom end, which could be considered less reliable in their abundance. This is 
important to take into account in later parts of the analysis and especially when interpreting the 
differential expression results. 
 
4.2 Statistical methods 
 
Once the processed and quantified protein abundance data were obtained, the next step is to apply 
statistical methods to it in order to identify interesting proteins or any possible patterns between the 
treatments. In the following subsections, the statistical methods applied to IOBA-NHC and HCE data 
are described. Where applicable, some further descriptions about both of the datasets are included but 
majority of the actual analysis and results are explained and illustrated then in the following sections 
(see sections 5 and 6). 
 
4.2.1 Data processing – from raw data to quantified protein measures 
 
Altogether 2299 and 1920 proteins, all with a unique International protein index (IPI) and associated, 
not necessarily unique, gene symbol accession, were relatively quantified for the IOBA-NHC and 
HCE cell line samples respectively. The relative quantification step used a SWATH library for >2700 
proteins as a reference and this library was created from the samples. 
 
Preservative Preservative Preservative-free 
Treatment BAC Latanoprost Tafluprost Control 
Biological 
replicate 
1 2 3 1 2 3 1 2 3 1 2 3 
Technical 
replicates 
1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 
Table 4.1.2 Two technical replicates were produced of each biological replicate and the data structure of IOBA-
NHC cell line is shown here as an example. HCE cell line data structure is highly similar though the number of 
biological replicates for each treatment is only two. 
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4.2.2 Reduction of bias and checking for data quality 
 
First, log2-transformation was applied to the data and as the number of quantified proteins was 
relatively high for proteomic data, and some variability between biological replicates and their 
medians were observed for both cell lines, a central tendency normalization was applied to the data 
after log2-transformation. Other normalization methods were also tested, e.g. loess normalization, 
which also accounts for the aforementioned trend bias, and quantile normalization. However, these 
alternative methods did not result in any considerable improvements in the data. 
Quality of the data, in the case of technical replicates in particular, was in addition checked prior and 
after the transformation and normalization steps. This was performed by producing MA-plots, 
correlations coefficients for technical replicates (Spearman’s rank correlation coefficient) and 
visualizations applying hierarchical clustering. 
 
4.2.3 Differential expression analysis 
 
Once it had been established that the data was adequately preprocessed, the next step involved 
differential expression analysis. More specifically it was checked, if any statistically significant 
differences will arise between the preservative-free and preservative-treated samples. As mentioned, 
the differential expression analysis, similar to all of the earlier steps, was done separately for the 
IOBA-NHC and HCE cell line data. 
The presence of technical replicates in the data means that the chosen statistical model should be able 
to account for the multiple “layers” in the data. Note, that not only should the non-independence of 
the technical replicates be accounted for, but also the nested structure of the preservative-free 
(tafluprost and control) and preservative-treated (latanoprost and BAC) samples needs to be included 
in the model. 
By including both latanoprost- and BAC-treated samples under the preservative-treated factor, the 
full effects of BAC-treatment, and in particular the potential proteins affecting the development of 
BAC-induced adverse effects in topical treatments could be better discovered. Same applies to the 
preservative-free group, which naturally includes both control and tafluprost-treated samples. The 
model was implemented using lme4 package in R and lmer function in it in particular. The resulting 
model, in terms of R code, is shown below: 
         𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑎𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 ~ 𝑝𝑟𝑒𝑠𝑒𝑟𝑣𝑎𝑡𝑖𝑣𝑒 +  (1|𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡: 𝑠𝑎𝑚𝑝𝑙𝑒) + (1|𝑠𝑎𝑚𝑝𝑙𝑒: 𝑟𝑢𝑛)      (3) 
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In the above function, the protein abundance is a continuous variable whilst the independent variables 
are all nominal. Here, the last two terms starting with “(1|” show the random effects and the “:” 
symbols indicate, that the factors are nested within each other. For example, as is known, there are 
two runs (technical replicates), which relate to the same sample (biological replicate). This model is 
not stating the additional i.i.d. residual error but it should be considered to be part of the model. In 
addition, below are the statistical hypothesis relating to this statistical model: 
𝐻0: There is no difference between the protein abundance levels of the preservative-free and 
preservative-treated samples. 
𝐻1: There is a difference between the protein abundance levels of the preservative-free and 
preservative-treated samples. 
It should be noted that the lmer function does not supply p-values for the coefficients and hence these 
were separately produced using varying methods, which were compiled in a text by Mirman (2014). 
As Mirman explains, the most conservative of the methods listed uses Kenward-Roger approximation 
to obtain approximate degrees of freedom and the t-distribution to get p-values. The results based on 
the less-conservative methods could have produced p-values with much higher initial FDR and hence 
Kenward-Roger approximation was implemented and more specifically the p-value derivation is 
implemented in the pbkrtest package in R. 
 
4.2.4 Establishing thresholds – fold change and p-value adjustments 
 
Benjamini-Hochberg, which allows to control the FDR, was implemented here to obtain the corrected 
p-values, i.e. q-values. In order to establish, which proteins have an interesting difference in 
abundance between preservative-free and preservative-treated samples, the groups of interesting 
proteins for IOBA-NHC and HCE cell line results were evaluated based on both their statistical 
significance (q-values) and biological effect size (log2 fold changes in this case).  
As the data in this study is now in log2 scale, the threshold for proteins of biological effect needs to 
be transformed to log2 scale as well, hence for example log2(2) for 2-fold changes. Both of the 
thresholds are applied to the results at the same time, which should ensure that the chosen proteins of 
interest have both statistical and biological significance. Because of this, and due to the initially 
conservative p-values, the traditional thresholds were slightly relaxed as described in the results. 
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4.2.5 Network reconstruction 
 
Next some networks were produced by reconstructing them using reverse engineering. More 
specifically, the algorithm used to achieve this is called ARACNE, Algorithm for the Reconstruction 
of Accurate Cellular Networks, which is available to use in R via several packages. In this study, 
minet package was used to pre-process the data and run the ARACNE algorithm (Meyer et al., 2008). 
Cytoscape (version 3.2.0) was then used to visualize the resulting potential connections (Shannon et 
al., 2003). 
 
4.2.6 Enrichment analysis 
 
In this study, several tools were tested for enrichments and these tests implemented both KEGG and 
GO terms. The tools used include freely available online tools The Database for Annotation, 
Visualization and Integrated Discovery, DAVID, (Huang et al., 2009 (1); Huang et al., 2009 (2)), 
Gene Ontology enRIchment anaLysis and visuaLizAtion tool, GOrilla, (Eden et al., 2009; Eden et 
al., 2007) and GSEA software provided by the Broad Institute (Subramanian et al., 2005; Mootha et 
al., 2003). 
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5 Results 
 
This section describes in further detail the results together with the analyses performed with the 
IOBA-NHC and HCE cell lines. In the following subsections, the results from both cell line analyses 
are shown, often side-by-side though some parts are kept separate, and the cell line specific results 
are then later on discussed in relation to each other together in more detail. In addition, any differences 
between the cell lines are examined. 
 
5.1 Descriptive statistics 
 
First aspect of interest was the number of proteins quantified from the samples; 2299 and 1920 
proteins were relatively quantified for IOBA-NHC and HCE cells respectively. Venn diagram in 
Figure 5.1.1 shows how many of these quantified proteins were found in both cell lines. It should be 
noted, that there are several proteins which are very similar in their function and annotation and only 
due to small variation they are not considered to be the same protein in the two cell lines and hence, 
with more relaxed matching, the figure in the overlapping section could be expected to be much 
higher. 
As discussed earlier, the data, after log2 
transformation, should be further normalized 
if seen necessary, and since there were some 
differences between the technical replicate 
distributions and more specifically their 
medians and variance (see Appendix A), this 
was deemed as an appropriate next step. The 
normalization was performed using the 
central tendency normalization by 
subtracting the sample-wise median from 
each sample-specific observation. 
1348 
IOBA-NHC HCE 
Figure 5.1.1 Venn diagram of the numbers of quantified 
proteins between the two cell lines, i.e. IOBA-NHC (grey) 
and HCE (blue). 
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In Figure 5.1.2, the protein expression 
level distributions for individual 
technical replicates can be seen post 
normalization. This normalization 
appears to have succeeded well for both 
cell lines as it can now be assumed that 
the protein expression levels in all 
biological samples are roughly similar 
to each other based on medians and 
variance (see Appendix A for 
comparison). As can further be seen 
from Figure 5.1.2, there are three 
biological replicates present in the 
IOBA-NHC cell line (A) and two 
biological replicates for the HCE cell 
line (B) and each biological replicate 
has two technical replicates. 
Figure 5.1.3 shows the discretized 
protein abundance levels in heat maps 
for both cell lines separately. 
Discretization, i.e. binning, into 10 
categories was applied to the data due to the large homogeneity of the datasets and the few higher 
outliers, which otherwise would have prevented efficient visualization of differences between the 
samples. The dendrogram in the top shows the hierarchical clustering of the samples and this is 
similarly done to proteins in the rows, though the names of the proteins are omitted due to their large 
number. The clustering here was performed using hierarchical clustering with complete linkage 
method and Euclidean distance as the similarity measure. 
As Figure 5.1.3 also suggests, the technical replicates are not highly dissimilar as is evident from their 
clustering close together for both cell lines. Further on, the control and tafluprost-treated samples are 
more often clustered together similar to samples treated with BAC and latanoprost. This is particularly 
true for the IOBA-NHC samples (A), and the smaller number of biological replicates in HCE data 
(B) could be causing the clustering becoming more ambiguous. Yet, some clearer differences between 
preservative-free and preservative-treated samples appear to be evident for the HCE cell line. The 
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Figure 5.1.2 Boxplots of protein expression levels post normalization 
for (A) IOBA-NHC cell line and (B) HCE cell line. Normalization 
was performed on log2-transformed data using central tendency 
normalization. 
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clustering is not perfect for either of the cell lines and this would not be expected either as all 
identified proteins are included in this plot. 
 
  
Figure 5.1.3 Heat maps of the discretized expression levels between all samples for (A) IOBA-NHC and (B) HCE cell 
lines. Hierarchical clustering using Euclidean distance was applied in the clustering and generation of dendrograms. The 
number following the treatment name tells the sample number and the final figure tells the technical replicate number. As 
described by the colour keys, green signifies highly expressed proteins and red indicates that the expression level is 
relatively low in comparison to other proteins on average. BAC- and latanoprost-treated samples cluster frequently close 
to each other in both cell lines similar to control and tafluprost-treated samples. 
 
The quality of technical replicates was further evaluated by calculating the Spearman’s correlation 
coefficient and the connected p-value for all technical replicates. For all technical replicates, the 
correlation coefficient was well above 0.9 and in fact the minimum coefficient was 0.9489 and largest 
p-value obtained was 2.2e-16, which is still considerably small. In addition, the MA-plots (Appendix 
B) did not show any worryingly large trends between the technical replicates. Hence, the technical 
replicates appear to be considerably similar and no exclusions are necessary. The preliminary 
descriptive visualizations and statistics described in this subsection do suggest that the data are of 
sufficient quality. 
As mentioned, other normalization methods, e.g. quantile normalization, were tested but these options 
were discarded as they did not appear to improve the quality of data. In fact, it appears that these 
“stricter” methods cause a larger loss information which is necessarily no longer due to bias. This 
type of approaches can be more relevant with data containing more quantified proteins or for example 
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mRNA. Indeed quantile normalization is often used to eliminate bias from mRNA or similar data 
which can include hundreds of thousands of different mRNAs.  
 
5.2 Differential expression 
 
This subsection will have the IOBA-NHC and HCE cell lines separated, which will enable more 
detailed analysis of the results for both cell lines and hopefully to avoid confusion between the results 
and their corresponding interpretations.  
 
5.2.1 Differential expression analysis for IOBA-NHC 
 
The differential expression analysis was performed using mixed-effects model as described 
previously and the multiple correction issue was accounted for by adjusting the p-values based on 
Benjamini-Hochberg correction, which results in q-values. Figure 5.2.1.1 displays the results from 
the differential expression analysis. The chosen thresholds for this cell line, once taking into account 
the conservative nature of the original p-values and the fact that two different thresholds are applied 
to the results, were chosen to be >1.25 and <0.8 for the fold change and <0.25 for the q-values. 
Effectively, values satisfying the fold change and the q-value thresholds are considered interesting 
and potentially significant both statistically and biologically. In Figure 5.2.1.1 these proteins are 
colored red and they are also further named (gene symbol ID) in the volcano plot. 
A few proteins pop out from the plot. In general, interesting proteins include the ones, which are 
mapped very high in relation to the y-axis, i.e. they have a very low q-value, and hence even lower 
original p-value. In the case of IOBA-NHC, proteins satisfying this criteria include at least 
hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1), NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 3, mitochondrial (NDUFS3) and NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 5 (NDUFA5). These proteins are all under-expressed in the BAC-treated 
samples.  
It should be noted that General transcription factor 3C polypeptide 4 (GTF3C4), is likely to have 
obtained its significance due to very large variability which becomes evident when plotting the 
observed values of this protein and it is unlikely, that there would be a truly significant difference 
between the preservative-free and preservative-treated samples in the case of this protein. 
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Figure 5.2.1.1 Volcano plot of IOBA-NHC data analysis results. The x-axis represents the biological effect size, fold 
change (in log2 scale) so that proteins at the far left in this scale can be considered to be under-expressed in preservative-
treated samples. The proteins in the far right are then over-expressed in the preservative treated samples. The y-axis 
displays the statistical significance scale, the least statistically significant proteins being at the bottom close to zero. 
Proteins, which have a q-value below 0.25 and fold change above 1.25 or below 0.8 are named and labelled red. 
 
As already mentioned previously, the order of the proteins is an aspect which should be kept in mind 
since the proteins higher in the list can be considered to be more reliable. Table 5.2.1.2 lists the 
proteins of interest, i.e. proteins which satisfy the chosen thresholds, together with their corresponding 
log2 fold changes and p-values (both non-adjusted and adjusted). More specifically, as a result the 
statistical analysis 29 differentially expressed proteins were identified for IOBA-NHC cells (fold 
change>1.25 or <0.8, q-value<0.25). This table shows the proteins in the order they were discovered 
in the loop, hence the proteins, their expression levels and hence, their results in the top rows can be 
considered to be of higher quality than the ones in the bottom rows. 
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Gene symbol IPI Log2 fold change P-value Adj. p-value 
PYGL IPI00943894.1 0.434 0.005 0.190 
HADHA IPI00031522.2 -0.518 0.004 0.175 
HNRNPA1 IPI01022801.1 -0.349 0.008 0.221 
HMGCS1 IPI00963899.3 -0.580 0.000 0.004 
PYGB IPI00004358.4 0.324 0.002 0.112 
DDX21 IPI00015953.3 -0.562 0.001 0.091 
HADHB IPI01018954.1 -0.362 0.003 0.142 
HMGB2 IPI00219097.4 0.416 0.009 0.222 
AIP IPI00953925.1 0.330 0.009 0.222 
AP3D1 IPI00411453.3 0.460 0.009 0.222 
RTCD1 IPI00011726.1 -0.392 0.002 0.112 
GTF3C4 IPI00016725.2 3.015 0.006 0.191 
HK2 IPI00917193.1 -0.759 0.005 0.190 
MCTS1 IPI00179026.2 -0.498 0.008 0.221 
GALK1 IPI00940264.1 0.363 0.001 0.085 
KIAA0101 IPI00014147.3 -0.651 0.001 0.109 
CYP51A1 IPI01013163.2 -0.979 0.002 0.112 
MRTO4 IPI00106491.3 0.553 0.004 0.164 
PSMB8 IPI01017933.1 1.333 0.008 0.220 
NDUFA5 IPI00412545.4 -0.410 0.000 0.023 
MACROD1 IPI00155601.1 -0.684 0.007 0.203 
UBE2Z IPI00829749.2 0.763 0.009 0.222 
NDUFS3 IPI00025796.3 -0.395 0.000 0.004 
FMR1 IPI00872761.2 1.260 0.010 0.227 
NUP54 IPI00386702.1 0.380 0.012 0.237 
INHA IPI00007080.1 0.534 0.000 0.058 
TPP1 IPI00554617.2 -0.387 0.010 0.225 
B4GALT5 IPI00011656.1 -0.418 0.001 0.091 
MRPS35 IPI00073779.1 -0.410 0.010 0.227 
 
 
 
Table 5.2.1.2 Values for interesting proteins, i.e. proteins which have a fold change > 1.25 
or <0.8 and q-value < 0.25, in IOBA-NHC cell line in the order of quality of quantification. 
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Figure 5.2.1.3 visualizes the 
protein expression levels for the 
statistically significant proteins 
which were listed above. This 
time, the expression levels are 
again discretized so that large 
values do not overshadow the 
smaller ones. As it can be seen 
from the figure, there are 
approximately as many over- 
and under-expressed proteins 
for this cell line when 
comparing the preservative-free 
and preservative-treated 
samples. The next question is, 
how these proteins are 
connected and how they can 
explain the results we see 
through observing the cells. 
 
5.2.2 Differential expression analysis for HCE 
 
Similar analysis, as was done for the IOBA-NHC cell line data in the previous subsection, was carried 
out for the HCE cell line as well. Hence, again this part of the analysis was performed using mixed-
effects model and the multiple correction issue is accounted for by adjusting the p-values based on 
Benjamini-Hochberg correction, which results in q-values. 
Figure 5.2.2.1 shows the relative biological and statistical significance of the proteins based on the 
differential expression analysis results. Some of the interesting proteins based on the figure above 
include myosin light polypeptide 6 (MYL6), myosin-9 (MYH9) and myosin regulatory light chain 
12A (MYL12A), which are all highly statistically significant and the biological significance is also 
consistently high for all of these proteins. In addition, HMGCS1 is again under-expressed in the BAC-
treated samples almost exactly in the same biological and statistical significance level as in IOBA-
NHC cell line. It would appear that this protein is playing a role in both cell lines possibly in similar 
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Figure 5.2.1.3 Heat map of proteins, which displayed statistically significant 
(fold change > 1.25 or < 0.8 and q-value < 0.25) expression levels in IOBA-
NHC data. The red colour indicates lower expression and green alternatively 
tells of higher expression levels. 
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aspects. However, as the biological effect threshold is higher for HCE cell line since it has in relation 
much higher number of statistically significant proteins, the values corresponding to HMGCS1 are 
not shown in the following table. 
 
Figure 5.2.2.1 Volcano plot of HCE data analysis results. The x-axis represents the biological effect size, fold change (in 
log2 scale) so that proteins at the far left in this scale can be considered to be under-expressed in preservative-treated 
samples. The proteins in the far right are then over-expressed in the preservative treated samples. The y-axis displays the 
statistical significance scale, the least statistically significant proteins being at the bottom close to zero. Proteins, which 
have a q-value below 0.25 and fold change above 1.25 or below 0.8 are named and labelled red. 
 
In the volcano plot, the thresholds used were the same as with the IOBA-NHC but in Table 5.2.2.2 
the fold change threshold has been increased to 1.5 as the number of interesting proteins here was 
already relatively high as already mentioned previously. By increasing the threshold for the biological 
significance, the number of proteins of interest was now roughly similar for both cell lines. Hence, as 
a result 28 proteins were identified as statistically and biologically significant for HCE cells (fold 
change>1.5 or <0.67, q-value<0.25). In addition, it should be noted that a fold change threshold of 
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1.5 is more traditional and hence, it can be assumed that these results were more reliable than some 
of the ones obtained with the IOBA-NHC cell line data. 
 
 
Gene symbol IPI Log2 fold change P-value Adj. p-value 
MYH9 IPI00019502.3 1.219 0.000 0.069 
HSPD1 IPI00784154.1 0.714 0.008 0.239 
KRT19 IPI00479145.3 0.772 0.016 0.244 
SHMT2 IPI00789370.3 0.698 0.002 0.157 
NCAPD2 IPI00299524.2 -0.900 0.007 0.239 
GOT2 IPI00018206.4 0.641 0.005 0.239 
OAT IPI00022334.1 0.586 0.002 0.155 
HSPE1 IPI00220362.5 0.714 0.010 0.244 
GLUD1 IPI01014382.2 0.704 0.011 0.244 
MYL12A IPI00220573.4 1.475 0.000 0.014 
MYL6 IPI00796366.2 0.741 0.000 0.069 
DRG1 IPI00031836.3 -0.651 0.010 0.244 
UQCRC1 IPI00013847.4 0.697 0.013 0.244 
NIPSNAP1 IPI00894205.2 0.672 0.006 0.239 
OAS3 IPI01015393.1 0.862 0.012 0.244 
SSBP1 IPI00029744.1 0.589 0.015 0.244 
RAC2 IPI00010270.1 0.622 0.001 0.145 
PYCR1 IPI00941557.1 1.631 0.008 0.239 
GRPEL1 IPI00909181.1 0.753 0.010 0.244 
ARL6IP1 IPI01010487.1 1.163 0.007 0.239 
PRIM1 IPI00027704.5 -1.159 0.017 0.244 
CTSZ IPI00002745.1 0.646 0.005 0.239 
ERH IPI00029631.1 0.597 0.008 0.239 
LAMP1 IPI00884105.2 2.972 0.014 0.244 
KRT17 IPI00450768.7 0.704 0.002 0.155 
MARCKSL1 IPI00641181.5 1.247 0.017 0.244 
RG9MTD1 IPI00099996.2 1.387 0.018 0.246 
GNB1L IPI00107339.4 -1.916 0.010 0.244 
 
Table 5.2.2.2 Values for interesting proteins, i.e. proteins which have a fold change > 1.5 or 
<0.67 and q-value < 0.25, in HCE cell line in the order of quality of quantification. 
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The interesting proteins identified in 
the differential analysis shown in the 
previous table, are again clustered and 
visualized in a heat map in Figure 
5.2.2.3. The protein abundance is again 
discretized for better visualization. 
There is a considerably higher number 
of significant proteins, which are over-
expressed in BAC-treated samples in 
comparison to the preservative-free 
samples which was also evident from 
the volcano plot seen previously. 
Recall, that with IOBA-NHC this was 
approximately evenly halved for the 
“top” 29 proteins. 
 
 
 
 
 
5.2.3 Visualization of individual proteins of interest 
 
When keeping the thresholds same as previously described, i.e. 0.25 q-value and 1.25/0.8 or 1.5/0.67 
fold change for IOBA-NHC and HCE cell lines respectively, there are no statistically and biologically 
significant proteins, which would be found from both cell lines. This is unfortunate, as there was 
notably a large number of proteins, which were quantified for both cell lines. However, it would seem 
more reasonable to do this types of comparisons with exactly the same thresholds and hence,  whilst 
the q-value threshold was kept the same (0.25), the fold change threshold was set to look at proteins 
with fold change above 1.25 or below 0.8 for both cell lines. This way two proteins were identified 
to be present in both cell lines: HMGCS1 and HK2. The results for these proteins are shown next 
together with other interesting proteins, which were deemed statistically and biologically significant 
in only one cell line but are nevertheless in some way interesting and worthy of further investigation. 
HMGCS1 showed signs of under-expression with BAC treatment for both cell lines similarly (IOBA-
NHC: -0.58±0.07, p-value < 0.001, HCE: -0.57±0.05, p-value < 0.001). Its ranking was 239 and 211 
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Figure 5.2.2.3 Heat map of proteins, which displayed statistically 
significant (fold change > 1.5 or < 0.67 and q-value < 0.25) 
expression levels in HCE data. The red colour indicates lower 
protein abundance level and green alternatively tells of higher 
abundance. 
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in IOBA-NHC and HCE data respectively, which is relatively high in both cases and this suggests 
good accuracy of results. Figure 5.2.3.1 shows the expression levels for different treatments and this 
further clearly shows that the expression is much lower for cells treated with BAC, in both cell lines. 
 
 
 
 
 
 
Figure 5.2.3.1 The expression levels of HMGCS1 between different treatments for IOBA-NHC (A) and HCE (B) cell 
lines. It can be noted, that the relative expression levels are consistently lower for preservative-treated samples for both 
cell lines. 
 
HK2 expression levels in BAC-treated cells were under-expressed for IOBA-NHC (-0.76±0.21, p-
value 0.005) and over-expressed HCE (0.42±0.07, p-value = 0.001). The true significance of this 
protein is in this point difficult to determine as the ranking of this particular protein was 1176 for 
IOBA-NHC and 1169 for HCE and these larger values suggest, that the quality of measurements for 
this particular protein are not high. Hence, there should be more caution with this protein. Figure 
5.2.3.2 shows the expression levels for the cell lines and it demonstrates how the expression of control 
and Tafluprost samples is “flipped” between the cell lines.  
 
 
 
 
 
 
 
Figure 5.2.3.2 The expression levels for HK2 between different treatments for IOBA-NHC (A) and HCE (B) cell lines. 
The differences between the preservative-free and preservative-treated samples are not as clear as hoped. It appears that 
there is a large amount variability between the measurements. 
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Myosin-related proteins were over-expressed 
in the BAC-treated samples, but only in the 
HCE cell line. These clearly stood out from the 
rest of the proteins as highly statistically 
significant. Figure 5.2.3.3 shows the 
expression levels for these proteins in HCE 
samples and it can be clearly seen that the three 
proteins, more specifically MYH9 
(1.22±0.16, p-value < 0.001), MYL12A 
(1.48±0.11, p-value < 0.001) and MYL6 
(0.74±0.1, p-value < 0.001), had much higher 
expression levels for the BAC- and 
latanoprost-treated samples in all cases in 
comparison to the preservative-free 
treatments. 
Figure 5.2.3.4 visualizes differences between 
the treatments in IOBA-NHC cells. As it can 
be seen from the figure, both NDUFA5 (-
0.41±0.06, p-value < 0.001) and NDUFS3 (-
0.39±0.04, p-value < 0.001) had higher 
expression levels in tafluprost-treated and 
control samples in comparison to the two other 
treatments. The differences were not very 
large, but it could be thought that even small 
deviations from the norm could potentially 
cause changes in the cells. 
 
 
 
 
 
 
Figure 5.2.3.3 The expression levels between samples in 
HCE cell line for MYH9, MYL12A and MYL6. All three 
proteins had much higher expression levels for the BAC- 
and latanoprost-treated samples in all cases in comparison 
to the preservative-free treatments. 
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Figure 5.2.3.4 The expression levels between samples in 
IOBA-NHC cell line for NDUFA5 and NDUFS3. The 
relative differences between preservative-free and 
preservative-treated samples were not as large as for the 
previous proteins but it would still appear that the 
preservative-free samples have higher relative expression 
levels. 
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5.2.4 Network construction 
 
The next step in the analysis process was the network construction, which was performed by applying 
ARACNE algorithm based on the MI scores available for the protein pairs, as already described 
earlier. This was performed using the minet-package in R. Cytoscape was then used to visualize the 
resulting potential connections, which are visualized in Figures 5.2.4.1 and 5.2.4.2. Note, that the 
resulting graphs are mainly just additional visualizations of the results but the potential connections 
could also further give indication of the similar expression levels between proteins. 
 
Figure 5.2.4.1 Connections between the proteins deemed significant, based on both their biological and statistical effect 
size, for the IOBA-NHC cell line. The colour of the circle tells whether the protein is under- or over-expressed, green and 
red respectively, in the BAC-treated samples in comparison to the preservative-free samples. The size further indicates 
how statistically significant the protein is in terms of the differences. More specifically, the larger the circle, the more 
statistically significant the protein can be thought to be. 
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Figure 5.2.4.2 Connections between the proteins deemed significant, based on both their biological and statistical effect 
size, for the HCE cell line. The size and color of the circle are again descriptive of the statistical significance and 
expression level (see Figure 5.2.3.1 description). 
 
The visualizations were created with Cytoscape and they display connections deemed significant 
based on ARACNE algorithm. Any connections seen here could be deemed to be potential indicators, 
that the connected proteins display similar patterns in their abundance based on the data. From Figure 
5.2.4.1 it can be noted that HMGCS1, NDUFS3 and NDUFA5 are all connected based on the mutual 
information. These three proteins were in addition, the three perhaps most interesting proteins arising 
from the IOBA-NHC cell line results. Most notably, in Figure 5.2.4.2, the myosins (MYL6, MYL12A 
and MYH9) are all connected in the graph. Since the connections suggest that the data is “behaving” 
similarly with these proteins, this further support the findings that they all appear to be affecting the 
same functions in the cell.  
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5.3 Enrichment analyses 
 
In the next two subsection, the enrichment analysis results for GO and pathways are displayed. The 
analyses were carried out for both cell lines and these results are based on the earlier differential 
expression analysis results. 
 
5.3.1 GO enrichments 
 
The GO enrichments were tested with two different online tools: DAVID and GOrilla. The analyses 
were conducted differently; the enrichment analysis in DAVID was applied using a protein set, i.e. 
proteins of interest as specified in previous subsection, and a background of all quantified proteins. 
The enrichment analysis carried out with GOrilla, uses a list of all of the proteins, which were ordered 
based on the log2 fold change. One further difference between these two tools is that DAVID further 
on clusters the enriched GO terms together unlike GOrilla. 
 
DAVID 
DAVID tool clusters the enrichment results into groups that contain similar terms and gives an ES 
for the overall cluster. In Figure 5.3.1.1, the clusters are visualized for the three GO term groups, i.e. 
biological process, cellular component and molecular function, as indicated by their titles. 
Based on Figure 5.3.1.1 (A) and (B), these are no consistent enrichments between the two cell lines 
but when moved into the cellular components in Figure 5.3.1.1 (C) and (D), it can be noted that with 
both cell lines, the interesting proteins are highly concentrated on mitochondrion and other 
components, which could be closely associated to mitochondrion. In addition, HCE cell line also 
displays enrichments in myosin complex. Both cell lines also have enrichments in nucleotide binding 
in molecular functions (Figure 5.3.1.3 (E) and (F)). Note, that only the mitochondrion-related terms 
are statistically significant and these can be seen in more detail in Appendix C. 
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Figure 5.3.1.1 Clusters of enriched GO terms for IOBA-NHC and HCE cell lines. Biological process (A, B), cellular 
component (C, D) and molecular function (E, F) domains are all shown separately for the IOBA-NHC and HCE cell 
lines respectively. The horizontal axis shows the ES of the cluster and in general, the higher the ES, the more significant 
the cluster can be thought to be. All of the proteins associated to a given cluster, are shown inside the bars and the 
cluster name is given below the plot in the legend. The cluster naming was done so that it best describes the nature of all 
terms inside the cluster, whilst also taking into account the names which had the most statistically significant GO terms 
within the given cluster. See Appendix C for further information of the specific terms. 
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GOrilla 
As already discussed, ranking all of the proteins based on some significance measure, e.g. fold 
change, is another method of performing an enrichment analysis and this was essentially performed 
with GOrilla. In GOrilla tool, there are no annotation clustering possibilities and hence in the results, 
only the top 3 enriched GO terms for each cell line and GO term subgroup, when available, are listed. 
The ranking of enriched terms was done based on their q-values, i.e. p-values which have been 
corrected in order to account for the multiple testing, which also is present in the enrichment analysis 
results. No thresholds as such are applied here but the q-values should be kept in mind when making 
assumptions based on these results. 
It can be seen from Table 5.3.1.2 that the proteins, which are over-expressed in the presence of 
preservatives include many GO terms related to the actin filaments and cell adhesion for IOBA-NHC 
cell line and mitochondrion and translation for HCE cell line. The mitochondrion terms have a 
particularly low q-value. Individual proteins are not listed in the following results, as due to the nature 
of the test, a very large number of proteins is often included in one group. 
 
Table 5.3.1.2 Top 3 enrichment terms, where available, for both cell lines and for all three GO domains. The enrichment 
analysis is carried out ordering the log2 fold changes from positive to negative, i.e. the proteins over-expressed for 
preservative-treated samples are at the top and given most importance. The FDR q-value tells about the statistical 
significance of a given term. 
Cell line GO 
domain 
GO Term Description FDR q-
value 
IOBA-
NHC 
BP 
GO:0007614 short-term memory 6.86E-01 
GO:1903385 regulation of homophilic cell adhesion 7.17E-01 
GO:0030029 actin filament-based process 7.60E-01 
CC 
GO:0042995 cell projection 4.23E-05 
GO:0070062 extracellular exosome 1.48E-04 
GO:1903561 extracellular vesicle 1.85E-04 
MF 
GO:0008092 cytoskeletal protein binding 7.75E-03 
GO:0003779 actin binding 9.90E-03 
HCE 
BP 
GO:0043624 cellular protein complex disassembly 2.62E-03 
GO:0009056 catabolic process 2.75E-03 
GO:0006415 translational termination 2.91E-03 
CC 
GO:0044429 mitochondrial part 7.97E-22 
GO:0005759 mitochondrial matrix 9.70E-18 
GO:0070013 intracellular organelle lumen 6.27E-12 
MF 
GO:0003735 structural constituent of ribosome 1.75E-04 
GO:0003954 NADH dehydrogenase activity 1.36E-01 
GO:0051537 2 iron, 2 sulfur cluster binding 1.54E-01 
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On the other hand, when the proteins were ranked so that the highest ranking proteins corresponded 
to proteins, which were very highly expressed in preservative-free samples in relation to preservative-
treated samples, the results are different and they can be seen from Table 5.3.1.3. Now the IOBA-
NHC cell line displays enrichments in terms related to mitochondrion and translation as well as 
transcription and HCE cell line has various terms. All terms in HCE cell line have relatively high q-
values and this is expected as there were a very small amount of statistically significant proteins, 
which were over-expressed in the preservative-free samples. Overall, it would appear that the 
mitochondrion and its related structures are significantly enriched based on both online tools and 
hence both methods, i.e. protein set and ranked proteins.  
 
Table 5.3.1.3 Top 3 enrichment terms, where available, for both cell lines and for all three GO domains. The enrichment 
analysis is carried out ordering the log2 fold changes from negative to positive, i.e. the proteins under-expressed for 
preservative-treated samples are at the top and given the most importance. The FDR q-value tells about the statistical 
significance of a given term. 
Cell line GO 
domain 
GO Term Description FDR q-
value 
IOBA-
NHC 
BP 
GO:0000375 RNA splicing, via transesterification reactions 8.24E-05 
GO:0070124 mitochondrial translational initiation 8.72E-05 
GO:0000398 mRNA splicing, via spliceosome 1.23E-04 
CC 
GO:0044429 mitochondrial part 7.91E-08 
GO:0019866 organelle inner membrane 7.84E-07 
GO:0005743 mitochondrial inner membrane 2.74E-06 
MF 
GO:0001103 RNA polymerase II repressing transcription 
factor binding 
5.75E-02 
GO:0016655 oxidoreductase activity, acting on NAD(P)H, 
quinone or similar compound as acceptor 
1.06E-01 
GO:0016651 oxidoreductase activity, acting on NAD(P)H 1.12E-01 
HCE 
BP 
GO:1903008 organelle disassembly 3.27E-01 
GO:0018212 peptidyl-tyrosine modification 3.69E-01 
GO:0016126 sterol biosynthetic process 4.82E-01 
CC 
GO:0005665 DNA-directed RNA polymerase II, core 
complex 
8.08E-01 
MF 
GO:0004713 protein tyrosine kinase activity 5.95E-02 
GO:0003899 DNA-directed RNA polymerase activity 2.86E-01 
GO:0031267 small GTPase binding 2.95E-01 
 
 
5.3.2 Pathway enrichments 
 
The pathway enrichment analysis was performed using a tool provided by Broad Institute. Here the 
list of proteins was again ranked from the highest to lowest log2 fold change and the default software 
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settings were used to run the tests. Further on, all curated annotations were searched through all latest 
(version 5.0) curated KEGG annotations. Other annotation databases were also tested, but KEGG 
database appeared to produce more general and applicable information and when multiple databases 
were combined, the amount of information became overwhelming. KEGG enrichments were also 
tested using DAVID annotation tool but no further information was obtained this way. 
As it can be seen from Tables 5.3.2.1 and 5.3.2.2, the results are not highly significant for many of 
the pathways after adjusting for the multiple comparison. The two tables display only the KEGG 
terms, which had an unadjusted p-value below 0.3. Keeping the threshold high enables us to get a 
wider picture of the possible underlying pathways being affected, though the significance of the 
enrichment should also be kept in mind. Another aspect is that these enrichment results are merely 
guiding the discussion and any arising hypotheses should be further tested before any conclusions 
can be made. This naturally also applies to the other results shown in this subsection. 
 
Table 5.3.2.1 The most statistically significant results obtained from a pathway enrichment analysis for the IOBA-NHC 
cell line. The order tells which way the log2 fold changes were ordered, i.e. “neg” refers to enrichments in the proteins, 
which were under-expressed for the BAC-treated samples and vice versa for “pos”. Size shows how many proteins from 
the list were found to associate to any particular KEGG annotation. ES and NES refer to non-normalized and normalized 
ESs respectively and the final three columns refer to unadjusted (NOM p-val) and adjusted significance measurements. 
Order KEGG Annotation Size ES NES 
NOM 
p-val 
FDR 
q-val 
FWER 
p-val 
neg 
Spliceosome 81 -0.431 -1.549 0.008 0.796 0.563 
Butanoate metabolism 16 -0.578 -1.462 0.061 0.748 0.789 
Apoptosis 17 -0.538 -1.367 0.112 0.878 0.936 
Lysine degradation 15 -0.528 -1.288 0.178 0.997 0.986 
Valine, leucine and isoleucine 
degradation 25 -0.442 -1.253 0.172 0.952 0.993 
pos 
Pentose phosphate pathway 18 0.514 1.337 0.096 1.000 0.974 
Vascular smooth muscle 
contraction 18 0.520 1.333 0.137 1.000 0.976 
Lysosome 29 0.399 1.173 0.233 1.000 1.000 
Focal adhesion 39 0.368 1.133 0.261 1.000 1.000 
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Table 5.3.2.2 The most statistically significant results obtained from a pathway enrichment analysis for the HCE cell line. 
The same descriptions apply as with Table 5.3.2.1. 
Order KEGG Annotation Size ES NES 
NOM 
p-val 
FDR 
q-val 
FWER 
p-val 
neg 
Pyrimidine metabolism 31 -0.617 -1.774 0.002 0.073 0.081 
Purine metabolism 39 -0.546 -1.644 0.010 0.155 0.306 
Cell cycle 31 -0.510 -1.449 0.046 0.512 0.829 
Prostate cancer 16 -0.527 -1.307 0.153 0.921 0.981 
Pathways in cancer 47 -0.410 -1.249 0.141 0.989 0.997 
Chronic myelois leukemia 18 -0.488 -1.227 0.192 0.910 0.997 
MAPK signaling pathway 33 -0.424 -1.211 0.186 0.842 0.999 
Pentose phosphate pathway 18 -0.483 -1.196 0.229 0.788 1.000 
pos 
Arginine and proline metabolism 19 0.707 1.877 0.003 0.027 0.024 
Citrate cycle TCA cycle 19 0.663 1.786 0.000 0.047 0.081 
Alzheimers disease 23 0.590 1.667 0.015 0.089 0.207 
Fatty acid metabolism 15 0.618 1.535 0.033 0.196 0.514 
Ribosome 70 0.412 1.458 0.015 0.259 0.698 
Valine, leucine and isoleucine 
degradation 19 0.514 1.389 0.098 0.337 0.842 
Lysosome 28 0.411 1.247 0.166 0.590 0.982 
Adherens junction 20 0.440 1.237 0.182 0.543 0.985 
Parkinsons disease 15 0.473 1.218 0.236 0.526 0.987 
Tight junction 27 0.404 1.194 0.203 0.526 0.991 
 
The tables do not present any major results, which would be consistent between the two cell lines. 
However, there are individual terms relating to cell death in both cell lines when looking at the 
proteins which are under-expressed in BAC-treated samples, i.e. “Apoptosis” (IOBA-NHC) and 
“MAPK signalling pathway” (HCE). Furthermore, in the “pos”-designated rows, it can be noted that 
IOBA-NHC has “Focal adhesion” and HCE has “Adherens junction” and “Tight junction” and these 
can be thought to refer to BAC’s ability to break junctions between cells and this way enhance the 
entrance of the drug as well. Several terms refer to different metabolic pathways and citric acid cycle, 
mainly in HCE cell line.  
 
5.4 Summary 
 
The results of this study are shown in the subsections above and the results may include potential 
biomarkers for the adverse effects of BAC and the proteins identified as important or interesting can 
then be verified in further studies.  
54 
Statistical analysis identified 29 differentially expressed proteins for IOBA-NHC cells (absolute fold 
change > 1.25 or < 0.8, q-value < 0.25) and 28 for HCE cells (absolute fold change > 1.5 or < 0.67, 
q-value < 0.25). Many of the proteins identified are connected to mitochondrion as shown by the 
enrichment analysis results. 
Several results observed in this study strongly suggest that changes in mitochondrion functions are 
affected by exposure to BAC Furthermore, in both cell lines HMGCS1 had a similar protein 
expression level profile, where this protein’s expression levels were more specifically under-
expressed in the preservative-treated samples. In addition, in HCE cell line results, MYH9, MYL12A 
and MYL6 were over-expressed in samples treated with BAC and in IOBA-NHC cell line, NDFUA5 
and NDUFS3 were under-expressed for BAC-treated samples. These individual proteins and their 
functions, together with the other results seen in this section are discussed in further detail in the next 
section. 
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6 Discussion 
 
In this section the results from the previous section will be discoursed in particular with respect to the 
known effects of BAC cytotoxicity and other related biological and proteomic aspects. The two cell 
lines used in this study and their corresponding results are discussed in some parts separately but 
mainly in comparison to each other in order to understand the underlying mechanisms more in depth. 
 
6.1 Differential analysis 
 
Once the analysis was performed for all proteins in both cell line data, it was noted that the number 
of proteins with a relatively high fold change ratio and low adjusted p-value, i.e. q-value, was quite 
low for both cell lines. However, the relative number of proteins, with high statistical and biological 
significance, was higher for HCE cell line than it was for the IOBA-NHC cell line. This could be 
explained by the lower number of independent biological replicates for the HCE data, which could 
then lead to a higher proportion of false positives. However, the quality on the other hand is much 
higher for the HCE cell line, at least based on some of the initial visualizations and in fact 
normalization of this data would not have been necessary (see Appendix A) and it was performed just 
to be consistent with the other similar analyses. Hence, the reason for a higher number of interesting 
proteins is yet to be established. This does raise questions about the research settings and whether 
more samples should have been included in the study. 
It could be argued that the thresholds should be kept exactly the same for both cell lines but as there 
are naturally differences between the cell lines and the aim was to identify the “top” interesting 
proteins, this type of threshold approach seemed reasonable. This is particularly true, since this way 
it was possible to achieve groups of interest for both cell lines which had approximately the same 
number of proteins. With some parts, it could however make more sense to keep the thresholds 
consistent and one such is described in the next paragraph. 
Next subsections will discuss some of the individual proteins of interest, which were looked at in the 
previous section as well in terms of their results and visualizations. The proteins and their known 
functional properties in cells are explained and in the light of this information, further hypotheses are 
made of their possible connections to BAC-induced effects. 
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6.1.1 HMGCS1  
 
HMGCS1 is a cytosolic, soluble HMG-CoA synthase which, according to National Center for 
Biotechnology Information (NCBI) database, is connected to lipid metabolic process, response to 
cholesterol and drug as well as brain development. Perhaps one of the most important roles of this 
protein lies in the cholesterol biosynthesis, where HMG-CoA synthase plays a part as a catalyst (King, 
2015).  
Cholesterol most importantly contributes to the physical properties of the plasma membrane of cells. 
More specifically, it affects the thickness, permeability, fluidity and phase behavior (Crockett, 1998) 
as well as cell signaling (Sheng et al., 2012). In our results HMGCS1 was under-expressed for BAC-
treated samples, which could imply that less cholesterol would become available for the use of the 
cells. This could then in turn result in less stable plasma membranes in BAC-treated cells. It could be 
hypothesized that this in its part is affecting the cytotoxicity of the preservative since it is further 
already known that BAC does disturb the plasma membranes of both prokaryotic and eukaryotic cells. 
Note further, that interestingly lanosterol 14-alpha demethylase (CYP51A1), which is a cytochrome 
P450 enzyme, is also found in the list of interesting proteins in IOBA-NHC cell line (-0.98±0.24, p-
value = 0.002) and it happens to be an enzyme which is also involved in de novo cholesterol 
biosynthesis (King, 2015). 
 
6.1.2 HK2 
 
Hexokinase-2, i.e. HK2 is an enzyme involved in the glucose metabolism pathways according to 
information in NCBI. It is commonly located in the outer membrane of mitochondria and once 
dissociated from it HK2 triggers apoptosis via mitochondrial membrane permeabilization and release 
of apoptogenic proteins (Chiara et al., 2008). 
It should be recalled that the true significance of this protein is in this point difficult to determine as 
further the ranking of this particular protein was 1176 for IOBA-NHC and 1169 for HCE and this is 
not as high as one could have hoped for and the results and visualizations suggested that the actual 
underlying difference between samples with regards to this protein are not as clear as desired since 
the expression levels between preservative-free and preservative treated samples were “flipped” 
between the cell lines. Hence, there should be more caution about the actual significance of this 
protein with regards the BAC-induced effects. 
57 
6.1.3 Myosin enzymes 
 
Overall, there are not many groups of proteins that initially stand out from the list of proteins as 
similarly expressed but one group worth noting are the myosin-related proteins. There are already 
some previous studies which have identified that the myosins do play a role in BAC-induced 
inflammation (Guo et al., 2007; Droy-Lefaix et al., 2013). Myosins and their related myosin light 
chains (MLC), and more specifically the phosphorylation of MLC is needed to produce the 
contractions of the actin cytoskeleton and this event in turn regulates the barrier integrity, adhesion 
and migration. Furthermore, the study by Guo noted that exposure to BAC leads to a reduced 
phosphorylation of MLC, which in turns affects the contractility of the actin cytoskeleton and the 
maintenance of epithelial barrier suffers from these changes as the cell migration ability is reduced. 
Combined with reduced levels of proliferation and adhesion, adverse effects are likely to take place. 
MLC kinase phosphorylates the MLC whilst MLC phosphatase dephosphorylates it. The combination 
of these two events results in cell migration. As the cytoskeleton contracts, it can be further thought 
that the paracellular permeability is increased as the intercellular tight junctions are opened. A study 
by Droy-Lefaix et al. (2013) based their starting point on this information and evaluated how the 
inhibition of MLC phosphorylation affected the BAC-induced effects in the eyes of rats. According 
to their results, inhibition of cytoskeleton contractions via MLC kinase inhibitor reduces the 
inflammatory effects of BAC.  
It should be noted, that articles by Droy-Lefaix and Guo claim somewhat different things, but the 
main point remains the same; BAC is affecting the actin cytoskeleton contractions via MLC. Whether 
the inflammatory effects are caused by phosphorylation or dephosphorylation does not appear to be 
clear yet and more research is needed. Based on the results obtained from this study, it appears that 
the over-expression of the three myosins, or myosin light chains, mentioned does suggest increased 
mobility of the cells and it could be expected that the adhesion is this way also increased as described 
by Droy-Lefaix. Based on these results, it is not difficult to believe, that inhibition of MLC could 
reduce the inflammation in eyes, or at least reduce some of the adverse effects. 
 
6.1.4 Mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) 
 
It has already been discussed previously that BAC is inducing oxidative stress in human conjunctival 
cells and the under-expression of both NDUFA5 and NDUFS3 in the IOBA-NHC cell line results 
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appears to further confirm these observations. These two proteins are subunits of the mitochondrial 
membrane respiratory chain NADH dehydrogenase (Complex I), which will be referred to simply as 
Complex I here. When Complex I becomes inhibited, as has happened with the preservative-treated 
samples in IOBA-NHC cells in this study, the production of reactive oxygen species (ROS) is 
increased (Raha & Robinson, 2000; Fato et al., 2009). Similar results were shown in an article by 
Nianyu et al. (2003), where rotenone, which inhibits Complex I, was shown to induce apoptosis by 
affecting the ROS production. Based on this, it could be hypothesised that the two proteins discussed 
here, and their under-expression is causing apoptosis of IOBA-NHC cells via ROS induced oxidative 
stress. 
 
6.2 Enrichment analyses 
 
Next the results obtained from the enrichment analyses are discussed. These results are largely 
complementing many aspects conversed in the previous subsections when interesting individual 
proteins and their potential effects were discussed. 
The enrichment results from DAVID had the highest ESs for “Generation of precursor metabolites 
and energy” for IOBA-NHC cell line and “Actin filament-based process” for HCE cell line in the 
biological process domain. These results support the evidence provided by some of the statistically 
significant proteins discussed earlier. More specifically, this could further strengthen the arguments 
about conjunctival cells experiencing oxidative stress due to defects in the electron transport chain as 
a result of exposure to BAC. Additional proteins affecting the enrichment of this term, in addition to 
NDUFA5 and NDUFS3, were glycogen phosphorylases, liver form (PYGL) and brain form (PYGB) 
and HK2. Further on, the actin filament-based movement was also discussed earlier in relation to 
myosin enzymes and as expected, MYL6 and MYH9 are associated to this GO term together with 
keratin, type I cytoskeletal 19 (KRT19) and Ras-related C3 botulinum toxin substrate 2 (RAC2). 
For both cell lines, the highest scoring terms in the cellular component domain were connected to 
mitochondrion and its parts. This further suggests, that BAC is largely affecting the mitochondrion 
and more studies are needed to investigate, what exactly is happening. One likely explanation is that 
BAC is causing instability in the mitochondrion membranes and, together with disrupting the 
respiratory chain functions, it could even cause lysis of this organelle structure. The destruction of 
mitochondrion, would result in apoptosis as this event would initiate apoptosis in cells. 
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The enrichment results achieved from GOrilla tool were slightly different, though the mitochondria 
and its parts were again highly enriched for the HCE in relation to proteins over-expressed in BAC-
treated samples and for the IOBA-NHC in relation to proteins under-expressed in BAC-treated 
samples. The terms related to the mitochondrion were the most statistically significant terms in these 
results. It should be noted that the tables describing the results do contain some terms which have a 
very high, i.e. non-significant, q-values. These are nevertheless included in order to describe the top 
terms regardless of their individual statistical significance. 
Furthermore, IOBA-NHC cell line results relating to the proteins over-expressed in the BAC-treated 
samples suggested that there were enrichment in relation to extracellular exosomes and actin binding. 
The actin binding again suggests increase in cell mobility and adhesion, but this time in IOBA-NHC 
cell line. The extracellular exosomes can be related to several cell functions but it is generally 
accepted, that they are playing a part in cell signaling and they can be connected to inflammation and 
immune system. In addition, interestingly, exosomes are thought be produced by cells to avoid 
accumulation of drugs or waste (van der Pol et al., 2012). Hence, potentially these extracellular 
vesicles are formed in conjunctiva cells in attempt to remove BAC-associated waste from them. 
Enrichments with proteins, which were under-expressed in the BAC-treated samples did not result in 
any statistically significant results for HCE cell line but, as mentioned, IOBA-NHC cell line includes 
statistically significant terms relating to mitochondrion in cellular component domain and 
furthermore to mitochondrial translation initiation and mRNA splicing in biological process domain. 
This would suggest, that translation of mitochondrial genome is reduced and since the genome located 
in the mitochondria encode proteins related to the respiratory chain complex, this could further in its 
part explain how this pathway is interrupted with BAC (Kuzmenko et al., 2014). 
Final part of the enrichment analysis consisted of the pathway enrichments, which unfortunately did 
not result in any further consistent and statistically significant results for IOBA-NHC cell line, 
although terms such as “apoptosis” and “focal adhesion” were mentioned. These terms had still such 
high p- and q-values that it is perhaps unnecessary to start forming specific hypotheses based on them. 
However, it could be argued that BAC is somehow affecting the energy production in cells, possibly 
via mitochondrion, which is then resulting in unwanted and apoptotic effects in the affected cells. 
For HCE cell line only a few interesting terms appeared when results were ordered in such a manner 
that the proteins, which were over-expressed in the BAC-treated samples were on the top. According 
to the pathway enrichments, when the HCE cells are treated with BAC, this may affect the cells’ 
citrate cycle and arginine and proline metabolism. However, based on my personal experience with 
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this tool, the latter term appears to be very frequently in the top enrichment results. Hence, the main 
interest should be on the first term mentioned, which also refers that the main BAC-induced effects 
are affecting the mitochondrion and its related functions. 
 
6.3 Data assessment 
 
This subsection will discuss some of the issues relating to the sample processing and data analysis. A 
critical approach is taken to evaluate the successfulness of the research overall and the ability to 
answer the proposed research questions. Some of the topics discussed here are not necessarily issues 
but merely thoughts about the data and methods used, which arose in the process of writing the study.  
It should be noted, that there are no ethical issues relating to this study, as cell lines were used to 
perform this study. Since cell lines were used, the results should be treated carefully as the situation 
in real-life could differ from the results in some aspects. However, this should not be a major concern 
as the cell lines in this study have been studied extensively in similar studies and they have been 
estimated to represent the actual human epithelial conjunctival and corneal cells well (as mentioned 
previously). For the HCE cell line, another commercially available untransfected cell line is the 
Wong-Kilbourne derivative of Chang conjunctival cell line. Unfortunately, this cell line is reported 
to suffer from contamination with HeLa cells. However, it has also been noted that IOBA-NHC cells 
do show some differences in phenotypic and karyotypic patterns in comparison to normal 
conjunctival epithelium (Brasnu et al., 2008b). Brasnu et al. (2008b) also identified further small 
differences between these two cell lines. Chang cells could be more sensitive towards the effects of 
BAC despite the reported contamination. However, the study concluded that both cell lines can be 
useful in toxicological in vitro studies. 
In addition to the SWATH data, the data was also produced using iTRAQ-labeling method. However, 
the protein quantification steps prior to any further data analysis were not successful and hence, this 
data was discarded. This does not affect the results here, though it would have been interesting and 
informative to compare the results obtained in these two different methods. Perhaps some further 
confirmation of the significance of some of the proteins could have been confirmed. However, this 
can be similarly achieved in further studies which are currently being carried out for more treatments, 
including the ones mentioned in this study. 
The data annotation was performed with IPI annotations as previously mentioned. However, IPI 
database was discontinued in September 2011 and unfortunately for this data, the switch to mapping 
61 
with UniProt Knowledgebase was not yet completed and as a result the data were mapped using 
potentially outdated IPI accessions. However, as the gene symbols were additionally readily available 
in the data, majority of the proteins could be quite easily mapped to known genes or proteins. Yet, in 
an ideal case, the proteins accessions would have been according to the new recommendations (Griss 
et al., 2011). 
Another aspect, again this cannot be considered as an issue per se, but more as an aspect to keep in 
mind, is that the cells’ exposure to any given treatment is 24 hours. One of the topics of this study 
discusses how the preservatives are affecting sensitive patients, who are exposed to these treatments 
often for extensive periods of time, i.e. years or decades. Hence, a cell line’s exposure to the treatment 
for only 24 hours is not fully comparable to this, and it is not attempted either. This study merely tries 
to enlighten some of the possible early steps occurring in the corneal and conjunctival cells and the 
reality in patients could naturally be very different from this, and from each other.  
Furthermore, it would have been interesting, if the concentrations of BAC, and naturally other 
treatments, had been varied in this study, which could further verify the obtained results. Incidentally, 
this is being done in the next related study, which is being processed currently. 
One of the main issues affecting the data analysis quality of the study in my opinion was the number 
of biological samples as this was rather small for HCE cell line in particular. Ideally, the number 
should have been higher than two or three, which was not the case here. Small number of biological 
replicates can result in reduced quality of results as the number of false positives and negatives can 
rise. However, this problem becomes more significant when the quality of measurement techniques 
is not good to begin with. In this particular study, as SWATH method was implemented in the protein 
quantification, I would argue that the issue is not as severe as it could be with some other methods. 
Furthermore, it can be thought that the sensitivity was slightly increased by implementing the mixed 
effects model instead of merely taking the means of the technical replicates. Yet, in further studies, if 
the resources allowed, I would be inclined to wish for larger numbers of biological replicates per 
treatment. 
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7 Conclusion 
 
This study had more than one aim. First, it was performed in order to merely test if, and how well, 
this type of study would work out. More specifically, we were interested to examine how 
immortalized cell lines would respond to these treatments and how the resulting proteomics would 
turn out. This type of study has not previously been performed using MS SWATH method. As 
visualized in the results, we demonstrated that evidently this type of research is possible and it does 
produce some results, which are, based on technical replicates, of high quality, whilst still showing 
some interesting differences between the varying treatments. 
The aim of this study is not to tell that all preservatives are bad and should not be used in any topical 
treatments of glaucoma. Instead, it should merely be acknowledged that there is a subgroup of patients 
who are currently not benefitting from the medication provided for them. By examining the pathways 
and effects of BAC, perhaps some new approaches to the topical medications and their ingredients 
could be developed for these patients in particular. 
The second aim of this study, which is what this paper is mostly concentrating on is, what proteins 
are showing different abundance levels between the treatments and what could explain these 
differences in a larger, biological scale. It was hoped, that once these proteins, and their place in the 
vast network of biological processes was established, a few chosen ones could be further verified in 
following studies. Once a confirmation of the effects of BAC in a proteomic level can be achieved, it 
can hopefully help us in development of new medication or in fact new preservatives, which could 
be beneficial particularly to those patients needing long-term ophthalmic topical treatment who are 
sensitive to this very common preservative. 
Several results observed in this study strongly suggest that changes in mitochondrion functions are 
affected by exposure to BAC. This became evident not only from the enrichment analyses but it was 
also noted that in IOBA-NHC cell line, NDFUA5 and NDUFS3 were under-expressed for BAC-
treated samples. These proteins are associated to the mitochondrial membrane respiratory chain 
NADH dehydrogenase and once this process is inhibited, it is noted to increase ROS production, 
which could then in turn lead to oxidative stress. Furthermore, in both cell lines the cholesterol 
production and therefore the plasma membrane permeability and structure could be altered due to 
reduced abundance of HMGCS1, which is an essential catalyst in this process. It would further 
appear, with both individual proteins and enrichment results, that actin cytoskeleton contractions are 
at least in the HCE cell line increased, which then in turn affects the permeability of the cell junctions. 
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This was initially noted due to the over-expression of MYH9, MYL12A and MYL6 in HCE cell line 
samples treated with BAC. 
Together these results show not only supporting evidence of the previously conducted studies but 
also identify individual proteins, which could potentially play a key role in the effects induced in 
cornea and conjunctiva cells as a result of exposure to BAC. 
As already mentioned a few times, currently a new, very similar study is being carried out with more 
treatments. More specifically only IOBA-NHC cell are exposed to the treatments in this study and at 
least two new treatments are included in the study. These new added treatments are unfavorably 
affecting some patients but they do not contain BAC and hence it will be of interest not only to 
confirm some of the results seen in study but to also add more possible comparisons in the equation. 
Furthermore, the concentrations of treatments are also varied in this new study, which will further 
complicate the structure of statistical analysis but it is hoped to at the same time to provide more 
reliable answers to the current and future research questions. The processing and analysis of the 
samples will again be carried out using MS SWATH method. 
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 Appendix A – pre-normalized data 
 
 
 
Figure A-1 Boxplots of the non-normalized data. As it can be seen, the IOBA-NHC cell line data (A) suffers from more 
variation than the HCE data (B). The HCE data was in fact nearly perfect in terms of median and variance similarity. 
However, in order to be consistent with the data analysis, normalization was applied to both even though the effects on 
HCE data are likely to be very minor. 
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Appendix B – MA-plots of technical replicates 
 
 
Figure B-1 MA-plots of technical replicates for IOBA-NHC cell line data. These plots are based on the normalized data 
and the aim is to establish if there was any need for any other forms of normalization as well. It appears that there are no 
specific trends here as the red line (trend) is very flat, horizontal and close to the blue line which is a line specifying zero 
on y-axis. Also, the median in each plot is relatively close to zero, which further confirms, that the data is sufficiently 
normalized between the technical replicates and that they are of good quality. 
 
Figure B-2 MA-plots of technical replicates for HCE cell line data. These plots are based on the normalized data and 
similar to Figure B-1, the aim is to establish if there was any need for any other forms of normalization as well. Again, 
there are no worryingly large trends visible and the medians are close to zero. It can be concluded that the technical 
replicates are of good quality for this cell line as well.
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Appendix C – More detailed tables of the GO term enrichment results from DAVID 
 
Table C-1 Clustered enrichment terms under biological process domain for IOBA-NHC cell line results. 
Domain Cluster/ES Term Count PValue Gene symbol Fold 
Enrichment 
Bonferroni Benjamini FDR 
G
O
TE
R
M
_B
P
_F
A
T 
C
lu
st
er
 1
 -
 
En
ri
ch
m
en
t 
Sc
o
re
: 1
.4
0
 
GO:0006091~generation of precursor metabolites and energy 5 0.01 NDUFA5, PYGL, HK2, NDUFS3, PYGB 5.19 0.97 0.84 13.87 
GO:0019318~hexose metabolic process 4 0.03 GALK1, PYGL, HK2, PYGB 5.66 1.00 0.95 30.82 
GO:0005996~monosaccharide metabolic process 4 0.04 GALK1, PYGL, HK2, PYGB 5.10 1.00 0.95 38.55 
GO:0044275~cellular carbohydrate catabolic process 3 0.06 PYGL, HK2, PYGB 7.23 1.00 0.98 54.87 
GO:0016052~carbohydrate catabolic process 3 0.06 PYGL, HK2, PYGB 6.86 1.00 0.97 58.39 
GO:0006006~glucose metabolic process 3 0.11 PYGL, HK2, PYGB 4.87 1.00 0.98 80.51 
C
lu
st
er
 2
 -
 
En
ri
ch
m
e
n
t 
Sc
o
re
: 
1
.2
5 
GO:0006091~generation of precursor metabolites and energy 5 0.01 NDUFA5, PYGL, HK2, NDUFS3, PYGB 5.19 0.97 0.84 13.87 
GO:0016310~phosphorylation 4 0.07 GALK1, NDUFA5, HK2, NDUFS3 3.84 1.00 0.97 63.56 
GO:0006793~phosphorus metabolic process 4 0.11 GALK1, NDUFA5, HK2, NDUFS3 3.16 1.00 0.99 80.43 
GO:0006796~phosphate metabolic process 4 0.11 GALK1, NDUFA5, HK2, NDUFS3 3.16 1.00 0.99 80.43 
C
lu
st
er
 3
 -
 
En
ri
ch
m
en
t 
Sc
o
re
: 
0
.3
3 
GO:0006886~intracellular protein transport 3 0.32 AP3D1, NUP54, AIP 2.48 1.00 1.00 99.46 
GO:0034613~cellular protein localization 3 0.34 AP3D1, NUP54, AIP 2.35 1.00 1.00 99.67 
GO:0070727~cellular macromolecule localization 3 0.35 AP3D1, NUP54, AIP 2.33 1.00 1.00 99.70 
GO:0046907~intracellular transport 3 0.57 AP3D1, NUP54, AIP 1.52 1.00 1.00 100.00 
GO:0015031~protein transport 3 0.60 AP3D1, NUP54, AIP 1.45 1.00 1.00 100.00 
GO:0045184~establishment of protein localization 3 0.60 AP3D1, NUP54, AIP 1.45 1.00 1.00 100.00 
GO:0008104~protein localization 3 0.64 AP3D1, NUP54, AIP 1.34 1.00 1.00 100.00 
 
Table C-2 Clustered enrichment terms under biological process domain for HCE cell line results. 
Domain Cluster/ES Term Count PValue Gene symbol Fold 
Enrichment 
Bonferroni Benjamini FDR 
G
O
TE
R
M
_B
P
_F
A
T 
C
lu
st
er
 1
 -
 
En
ri
ch
m
en
t 
Sc
o
re
: 
0
.9
0 
GO:0030029~actin filament-based process 4 0.04 MYL6, KRT19, RAC2, MYH9 5.15 1.00 1.00 38.97 
GO:0030036~actin cytoskeleton organization 3 0.16 KRT19, RAC2, MYH9 3.94 1.00 1.00 91.31 
GO:0007010~cytoskeleton organization 3 0.34 KRT19, RAC2, MYH9 2.36 1.00 1.00 99.70 
C
lu
st
er
 2
 -
 
En
ri
ch
m
e
n
t 
Sc
o
re
: 
0
.8
0 
GO:0051345~positive regulation of hydrolase activity 3 0.04 SSBP1, HSPE1, HSPD1 8.60 1.00 1.00 44.66 
GO:0051336~regulation of hydrolase activity 3 0.11 SSBP1, HSPE1, HSPD1 5.11 1.00 1.00 78.59 
GO:0043085~positive regulation of catalytic activity 3 0.36 SSBP1, HSPE1, HSPD1 2.31 1.00 1.00 99.76 
GO:0044093~positive regulation of molecular function 3 0.41 SSBP1, HSPE1, HSPD1 2.08 1.00 1.00 99.92 
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Table C-3 Clustered enrichment terms under cellular component domain for IOBA-NHC cell line results. 
Domain Cluster/ES Term Count PValue Gene symbol Fold 
Enrichment 
Bonferroni Benjamini FDR 
G
O
TE
R
M
_C
C
_F
A
T 
C
lu
st
er
 1
 -
 E
n
ri
ch
m
en
t 
Sc
o
re
: 
0
.9
7 
GO:0031966~mitochondrial membrane 4 0.05 NDUFA5, HK2, NDUFS3, HADHA 4.44 0.99 0.99 43.34 
GO:0005739~mitochondrion 8 0.05 NDUFA5, MRPS35, TPP1, HK2, KIAA0101, MACROD1, 
NDUFS3, HADHA 
2.12 0.99 0.91 44.86 
GO:0005740~mitochondrial envelope 4 0.07 NDUFA5, HK2, NDUFS3, HADHA 3.94 1.00 0.87 53.84 
GO:0044429~mitochondrial part 5 0.10 NDUFA5, MRPS35, HK2, NDUFS3, HADHA 2.67 1.00 0.89 66.54 
GO:0031967~organelle envelope 5 0.11 NDUFA5, HK2, NUP54, NDUFS3, HADHA 2.57 1.00 0.86 70.70 
GO:0031975~envelope 5 0.11 NDUFA5, HK2, NUP54, NDUFS3, HADHA 2.57 1.00 0.86 70.70 
GO:0005743~mitochondrial inner membrane 3 0.15 NDUFA5, NDUFS3, HADHA 4.13 1.00 0.83 82.82 
GO:0019866~organelle inner membrane 3 0.19 NDUFA5, NDUFS3, HADHA 3.62 1.00 0.77 89.06 
GO:0031090~organelle membrane 4 0.34 NDUFA5, HK2, NDUFS3, HADHA 1.85 1.00 0.91 98.90 
C
lu
st
er
 2
 -
 E
n
ri
ch
m
en
t 
Sc
o
re
: 0
.5
8
 GO:0070013~intracellular organelle lumen 10 0.14 MRPS35, HMGB2, UBE2Z, RTCD1, FMR1, DDX21, NUP54, 
GTF3C4, HADHA, MRTO4 
1.53 1.00 0.88 79.71 
GO:0043233~organelle lumen 10 0.15 MRPS35, HMGB2, UBE2Z, RTCD1, FMR1, DDX21, NUP54, 
GTF3C4, HADHA, MRTO4 
1.52 1.00 0.85 81.59 
GO:0031981~nuclear lumen 8 0.16 HMGB2, UBE2Z, RTCD1, FMR1, DDX21, NUP54, GTF3C4, 
MRTO4 
1.65 1.00 0.81 84.70 
GO:0031974~membrane-enclosed lumen 10 0.16 MRPS35, HMGB2, UBE2Z, RTCD1, FMR1, DDX21, NUP54, 
GTF3C4, HADHA, MRTO4 
1.49 1.00 0.78 84.72 
GO:0005730~nucleolus 5 0.23 HMGB2, UBE2Z, FMR1, DDX21, MRTO4 1.91 1.00 0.83 94.28 
GO:0005654~nucleoplasm 5 0.28 HMGB2, RTCD1, FMR1, NUP54, GTF3C4 1.76 1.00 0.87 97.28 
GO:0043232~intracellular non-membrane-bounded organelle 7 0.86 MRPS35, HMGB2, UBE2Z, FMR1, DDX21, HADHA, MRTO4 0.85 1.00 1.00 100.00 
GO:0043228~non-membrane-bounded organelle 7 0.86 MRPS35, HMGB2, UBE2Z, FMR1, DDX21, HADHA, MRTO4 0.85 1.00 1.00 100.00 
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Table C-4 Clustered enrichment terms under cellular component domain for HCE cell line results. 
Domain Cluster/ES Term Count PValue Gene symbol Fold 
Enrichment 
Bonferroni Benjamini FDR 
G
O
TE
R
M
_C
C
_F
A
T 
C
lu
st
er
 1
 -
 E
n
ri
ch
m
en
t 
Sc
o
re
: 2
.1
8
 
GO:0044429~mitochondrial part 9 0.00 GOT2, SHMT2, GRPEL1, UQCRC1, SSBP1, NIPSNAP1, HSPE1, 
HSPD1, OAT 
5.46 0.01 0.01 0.08 
GO:0005743~mitochondrial inner membrane 5 0.00 GOT2, SHMT2, UQCRC1, NIPSNAP1, HSPD1 7.80 0.26 0.06 2.93 
GO:0019866~organelle inner membrane 5 0.00 GOT2, SHMT2, UQCRC1, NIPSNAP1, HSPD1 6.65 0.42 0.09 5.23 
GO:0031966~mitochondrial membrane 5 0.01 GOT2, SHMT2, UQCRC1, NIPSNAP1, HSPD1 6.50 0.45 0.08 5.70 
GO:0005740~mitochondrial envelope 5 0.01 GOT2, SHMT2, UQCRC1, NIPSNAP1, HSPD1 5.35 0.70 0.14 11.15 
GO:0031967~organelle envelope 6 0.02 GOT2, SHMT2, UQCRC1, RAC2, NIPSNAP1, HSPD1 3.31 0.95 0.28 24.83 
GO:0031975~envelope 6 0.02 GOT2, SHMT2, UQCRC1, RAC2, NIPSNAP1, HSPD1 3.31 0.95 0.28 24.83 
GO:0031090~organelle membrane 5 0.13 GOT2, SHMT2, UQCRC1, NIPSNAP1, HSPD1 2.44 1.00 0.76 78.44 
C
lu
st
er
 2
 -
 E
n
ri
ch
m
en
t 
Sc
o
re
: 2
.1
5
 
GO:0044429~mitochondrial part 9 0.00 GOT2, SHMT2, GRPEL1, UQCRC1, SSBP1, NIPSNAP1, HSPE1, 
HSPD1, OAT 
5.46 0.01 0.01 0.08 
GO:0005739~mitochondrion 11 0.00 GOT2, PYCR1, SHMT2, GRPEL1, UQCRC1, SSBP1, NIPSNAP1, 
RG9MTD1, HSPE1, HSPD1, OAT 
3.32 0.05 0.02 0.47 
GO:0031980~mitochondrial lumen 7 0.00 GOT2, SHMT2, GRPEL1, SSBP1, HSPE1, HSPD1, OAT 6.06 0.06 0.02 0.57 
GO:0005759~mitochondrial matrix 7 0.00 GOT2, SHMT2, GRPEL1, SSBP1, HSPE1, HSPD1, OAT 6.06 0.06 0.02 0.57 
GO:0070013~intracellular organelle lumen 8 0.47 GOT2, PRIM1, SHMT2, GRPEL1, SSBP1, HSPE1, HSPD1, OAT 1.19 1.00 1.00 99.93 
GO:0043233~organelle lumen 8 0.49 GOT2, PRIM1, SHMT2, GRPEL1, SSBP1, HSPE1, HSPD1, OAT 1.18 1.00 0.99 99.95 
GO:0031974~membrane-enclosed lumen 8 0.52 GOT2, PRIM1, SHMT2, GRPEL1, SSBP1, HSPE1, HSPD1, OAT 1.15 1.00 0.99 99.98 
C
lu
st
er
 3
 -
 E
n
ri
ch
m
en
t 
Sc
o
re
: 0
.7
6
 
GO:0016459~myosin complex 3 0.00 MYL6, MYL12A, MYH9 54.57 0.10 0.03 0.99 
GO:0015629~actin cytoskeleton 3 0.26 MYL6, MYL12A, MYH9 2.87 1.00 0.95 96.97 
GO:0044430~cytoskeletal part 4 0.50 MYL6, KRT19, MYL12A, MYH9 1.46 1.00 0.99 99.96 
GO:0005856~cytoskeleton 5 0.59 MYL6, KRT19, DRG1, MYL12A, MYH9 1.20 1.00 0.99 100.00 
GO:0043228~non-membrane-bounded organelle 9 0.65 MYL6, PRIM1, KRT19, SHMT2, SSBP1, DRG1, MYL12A, 
MYH9, NCAPD2 
1.03 1.00 1.00 100.00 
GO:0043232~intracellular non-membrane-bounded organelle 9 0.65 MYL6, PRIM1, KRT19, SHMT2, SSBP1, DRG1, MYL12A, 
MYH9, NCAPD2 
1.03 1.00 1.00 100.00 
C
lu
st
er
 4
 -
 
En
ri
ch
m
e
n
t 
Sc
o
re
: 
0
.5
0 
GO:0005886~plasma membrane 7 0.12 GOT2, LAMP1, KRT19, GNB1L, MARCKSL1, HSPD1, MYH9 1.93 1.00 0.77 76.41 
GO:0044459~plasma membrane part 4 0.33 LAMP1, GNB1L, HSPD1, MYH9 1.90 1.00 0.97 98.92 
GO:0016021~integral to membrane 3 0.48 LAMP1, HSPD1, MYH9 1.82 1.00 0.99 99.94 
GO:0031224~intrinsic to membrane 3 0.52 LAMP1, HSPD1, MYH9 1.67 1.00 0.99 99.98 
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Table C-5 Clustered enrichment terms under molecular function domain for IOBA-NHC cell line results. 
Domain Cluster/
ES 
Term Count PValue Gene symbol Fold 
Enrichment 
Bonferroni Benjamini FDR 
G
O
TE
R
M
_M
F_
FA
T 
C
lu
st
er
 1
 -
 E
n
ri
ch
m
en
t 
Sc
o
re
: 0
.8
4
 
GO:0048029~monosaccharide binding 3 0.01 GALK1, PYGL, HK2 17.46 0.71 0.71 11.59 
GO:0005529~sugar binding 3 0.02 GALK1, PYGL, HK2 11.91 0.93 0.73 22.95 
GO:0030246~carbohydrate binding 3 0.05 GALK1, PYGL, HK2 7.94 1.00 0.85 43.04 
GO:0005524~ATP binding 6 0.18 GALK1, UBE2Z, PYGL, RTCD1, HK2, DDX21 1.84 1.00 1.00 90.08 
GO:0032559~adenyl ribonucleotide binding 6 0.19 GALK1, UBE2Z, PYGL, RTCD1, HK2, DDX21 1.81 1.00 0.99 91.36 
GO:0030554~adenyl nucleotide binding 6 0.22 GALK1, UBE2Z, PYGL, RTCD1, HK2, DDX21 1.73 1.00 0.98 93.92 
GO:0001883~purine nucleoside binding 6 0.23 GALK1, UBE2Z, PYGL, RTCD1, HK2, DDX21 1.71 1.00 0.98 94.63 
GO:0001882~nucleoside binding 6 0.23 GALK1, UBE2Z, PYGL, RTCD1, HK2, DDX21 1.69 1.00 0.97 95.27 
GO:0032553~ribonucleotide binding 6 0.34 GALK1, UBE2Z, PYGL, RTCD1, HK2, DDX21 1.47 1.00 0.99 99.12 
GO:0032555~purine ribonucleotide binding 6 0.34 GALK1, UBE2Z, PYGL, RTCD1, HK2, DDX21 1.47 1.00 0.99 99.12 
GO:0017076~purine nucleotide binding 6 0.37 GALK1, UBE2Z, PYGL, RTCD1, HK2, DDX21 1.42 1.00 0.99 99.47 
GO:0000166~nucleotide binding 7 0.41 GALK1, UBE2Z, PYGL, RTCD1, HK2, DDX21, HADHA 1.29 1.00 0.99 99.78 
 
Table C-6 Clustered enrichment terms under molecular function domain for HCE cell line results. 
Domain Cluster/ES Term Count PValue Gene symbol Fold 
Enrichment 
Bonferroni Benjamini FDR 
G
O
TE
R
M
_M
F_
FA
T 
C
lu
st
er
 1
 -
 
En
ri
ch
m
e
n
t 
Sc
o
re
: 
1
.4
2 
GO:0070279~vitamin B6 binding 3 0.02 GOT2, SHMT2, OAT 14.41 0.72 0.47 15.34 
GO:0030170~pyridoxal phosphate binding 3 0.02 GOT2, SHMT2, OAT 14.41 0.72 0.47 15.34 
GO:0019842~vitamin binding 3 0.04 GOT2, SHMT2, OAT 8.65 0.97 0.57 35.97 
GO:0048037~cofactor binding 3 0.22 GOT2, SHMT2, OAT 3.23 1.00 0.94 92.82 
C
lu
st
er
 2
 -
 E
n
ri
ch
m
en
t 
Sc
o
re
: 0
.4
5
 GO:0051087~chaperone binding 3 0.01 GRPEL1, HSPE1, HSPD1 24.02 0.36 0.36 5.78 
GO:0051082~unfolded protein binding 3 0.12 GRPEL1, HSPE1, HSPD1 4.80 1.00 0.86 73.09 
GO:0017076~purine nucleotide binding 6 0.38 GRPEL1, RAC2, HSPE1, DRG1, HSPD1, MYH9 1.40 1.00 0.99 99.40 
GO:0032553~ribonucleotide binding 5 0.58 RAC2, HSPE1, DRG1, HSPD1, MYH9 1.20 1.00 1.00 99.99 
GO:0032555~purine ribonucleotide binding 5 0.58 RAC2, HSPE1, DRG1, HSPD1, MYH9 1.20 1.00 1.00 99.99 
GO:0000166~nucleotide binding 6 0.66 GRPEL1, RAC2, HSPE1, DRG1, HSPD1, MYH9 1.06 1.00 1.00 100.00 
GO:0030554~adenyl nucleotide binding 4 0.67 GRPEL1, HSPE1, HSPD1, MYH9 1.15 1.00 1.00 100.00 
GO:0001883~purine nucleoside binding 4 0.68 GRPEL1, HSPE1, HSPD1, MYH9 1.13 1.00 1.00 100.00 
GO:0001882~nucleoside binding 4 0.69 GRPEL1, HSPE1, HSPD1, MYH9 1.12 1.00 1.00 100.00 
GO:0005524~ATP binding 3 0.85 HSPE1, HSPD1, MYH9 0.91 1.00 1.00 100.00 
GO:0032559~adenyl ribonucleotide binding 3 0.85 HSPE1, HSPD1, MYH9 0.90 1.00 1.00 100.00 
C
lu
st
er
 3
 -
 
En
ri
ch
m
e
n
t 
Sc
o
re
: 
0
.1
1 
GO:0046872~metal ion binding 4 0.76 MYL6, PRIM1, UQCRC1, MYL12A 1.01 1.00 1.00 100.00 
GO:0043169~cation binding 4 0.77 MYL6, PRIM1, UQCRC1, MYL12A 0.99 1.00 1.00 100.00 
GO:0043167~ion binding 4 0.78 MYL6, PRIM1, UQCRC1, MYL12A 0.98 1.00 1.00 100.00 
 
